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The smoking epidemic is considered one of the main public health threats, ac-
counting for about 8 million deaths a year. It is estimated that there are currently 
more than 1 billion smokers in the world (WHO, 2020a).  
Smoking prevalence globally has declined during the last decades. Although 
there are differences between countries, the decrease in smoking is more pre-
valent among people with higher education and, furthermore among physicians, 
who can be considered to represent the higher socioeconomic bracket. However, 
according to the World Health Organization (WHO), among adults aged over 30 
years, more than 10% of all deaths are attributed to tobacco (WHO, 2012). Re-
ducing smoking will result in fewer deaths and less diseases like heart diseases, 
lung cancer, chronic respiratory diseases and other conditions (WHO, 2009). 
Tobacco smoking as a substance use disorder is considered a mental and 
behavioural disease in International Classification of Diseases (code F17 in 
ICD-10) (WHO, 2016). With tobacco smoke, more than 4,000 chemical com-
pounds and substances are released, including oxidative gases and heavy metals. 
Tobacco smoke contains at least 50 carcinogens (Florescu et al., 2009).  
Health care institutions have the obligation and opportunity to take the lead 
in tackling smoking, to reduce consumption of tobacco products and the impact 
of tobacco on health (Ministry of Social Affairs, 2014). Physicians are viewed 
as healthy lifestyle models by their patients and communities (Garfinkel, 1976) 
and are regarded as people from whom smokers would accept advice on 
smoking cessation (WHO, 2005). However, physicians’ own smoking habits 
and attitudes towards smoking affect the addressing of patients’ smoking 
(Abdullah et al., 2014; Meshefedjian et al., 2010; Pärna, et al., 2005a; Pipe et 
al., 2009).  
Quitting smoking can be challenging because of nicotine dependence (ND). 
Nicotine is the chemical compound in the tobacco plant. It has been found that 
tobacco addiction is similar to addiction to drugs such as heroin and cocaine 
(Hatsukami et al., 2008).  
In Estonia, smoking among the general population has been surveyed regu-
larly since 1990. However, among physicians in Estonia, the first survey was 
conducted already in 1978, followed by surveys in 1982, 2002 and 2014. Until 
now, no in-depth analysis based on the data from the surveys has not been 
conducted.  
The present study explores physicians’ smoking over three decades provi-
ding the opportunity to gain insight into the smoking trends, attitudes towards 
smoking behaviour, the readiness to address patients’ smoking and desire to 
quit smoking among a population that can be considered influential in terms of 
their profession. The study is also the first in Estonia to explore ND to such an 
extent.  
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2. REVIEW OF THE LITERATURE 
2.1. Definition of tobacco use and smoking 
In the context of the thesis, the terms concerning tobacco use and smoking are 
used as follows: 
 
Tobacco use Any habitual use of the tobacco plant leaf and its pro-
ducts; the predominant use of tobacco is by smoke inha-
lation of cigarettes, pipes, and cigars (Al-Ibrahim & 
Gross, 1990) but can also include sucking, chewing or 
snuffing any tobacco product.
Cigarette smoking The intended use of cigarette regardless of whether any 
and which means are used (Tobacco Act, 2005). 
Daily smoking Smoking currently at least one cigarette every day 
(CDC, 2011; NIHD, 2005; WHO, 1998).
Occasional smoking Less than daily smoking (NIHD, 2005; WHO, 1998) 
Current smoking currently smoking daily or occasionally.
Past (ex-) smoking Smoking daily previously but not currently (WHO, 
1998).
Never smoking Having never smoked at all or having never smoked 
daily and having smoked less than 100 cigarettes in life-
time (CDC, 2011; WHO, 1998).
E-cigarette Electronic cigarette (e-cigarette) is a product related to 
tobacco product that can be used for consumption of 
nicotine-containing vapour via a mouthpiece, or any 
component of that product, including a cartridge, a tank 
and the device without cartridge or tank  (Tobacco Act, 
2005).
Nicotine dependence An addiction to tobacco products caused by the nicotine.  
 
 
2.2. Measurement of smoking status 
Questionnaire-based measurement 
There can be different approaches to measuring smoking prevalence or as-
sessing smoking status among the population. The most widely used method is 
questionnaire-based survey, collecting self-reported data, usually conducted to 
explore health behaviour or smoking behaviour specifically.   
The advantage of questionnaire-based surveys is convenience, for both the 
researcher and for the respondents. Questionnaire-based surveys are cheaper 
compared to for example biomarker based studies and provide the opportunity 
to monitor larger populations (Florescu et al., 2009). By keeping the questions 
similar, this approach is suitable for assessing long-term trends in health beha-
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viour. The WHO has provided example questions and recommends their use so 
that the answers can be compared (CDC, 2011).  
Some of the limitations of collecting self-reported data include a possibility 
for classification- and recall-bias. The first means that a person might have 
difficulties determining their own smoking status based on the questions. The 
recall-bias makes it difficult to assess the quantities of the products used but 
also some important milestones in smoking behaviour, like initiation of 
smoking. The more time that has passed from the age of initiation of smoking, 
the more inconsistently it may be reported (Wellman & O’Loughlin, 2015). 
In some cases, the biases can be more common and can lead to underesti-
mation of smoking prevalence. This happens particularly in situations where 
social desirability is greater (Florescu et al., 2009), such as with children and 
adolescents, with pregnant women (Pärna et al., 2005c) and patients with 
conditions that are commonly associated with smoking (lung cancer, asthma, 
COPD) (Stelmach et al., 2015). Also among groups where setting a good 
example is important, like teachers and health care professionals. 
An important aspect to consider when using questionnaires, is the duration 
and intensity of smoking. For that, pack-year as a measure can be applied. Pack-
year is a unit that describes how much a person has consumed cigarettes during 
years and is calculated by multiplying the number of years of having smoked by 
the number of packs of cigarettes smoked per day. A pack is considered to con-
tain 20 cigarettes.  
 
Biomarker-based measurement 
Validation of self-reported data is possible when using biomarkers like cotinine, 
the metabolite of nicotine. Cotinine has a longer half-life (10 hours or more) 
compared to nicotine, and therefore allows to detect better whether a person has 
smoked, for example, if it was on the previous day.  
Cotinine level has been shown to correlate with cigarettes per day and time 
to first cigarette in the morning (Muscat et al., 2009; van Overmeire et al., 
2016), both of which are important measures of nicotine addiction, as well. 
Cotinine can be measured from urine, blood, saliva, and also from hair. By 
using relevant cut-off points (10–20 ng/mL for serum, 10–25 ng/mL for saliva, 
50–200 ng/mL for urine) (Kim, 2016), smokers can be distinguished from non-
smokers.  
However, there are several limitations for using biomarker-based measure-
ment. As the nicotine metabolism can be altered because of individual differen-
ces, the possibility of misclassification exists. For example, a second-hand smo-
ker could be classified as a smoker, or an occasional smoker as a non-smoker. 
This aspect has been considered an important limitation for using cotinine to 
validate self-reported smoking status. To overcome this limitation, it is sug-
gested that country-specific or multiple cut-off values of biomarkers for diffe-
rent exposure categories should be provided (Kim, 2016). Another limitation is 
that biomarkers are not best suited for use in population studies as they are 
time-consuming methods that require possibly expensive equipment.  
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Measuring cotinine from hair is non-invasive compared to drawing blood 
and has been shown to be an effective marker for assessing exposure to environ-
mental tobacco smoke among children. When cotinine levels from children’s 
hair were used to validate parents’ reports on smoking at home, the results re-
vealed that parents’ reports might not be compatible with the cotinine levels in 
their children’s hair (Gunay et al., 2020).  
 
Other possibilities 
Smoking behaviour among a smaller group can be accessed via direct observa-
tion, as well. This is also a time-consuming approach and is more suitable among 
very small populations for short periods of time. For example, in the United 
Kingdom, direct observation was used to assess compliance with smoke-free 
policies in hospitals (Ratschen et al., 2008). 
 
 
2.3. Measurement of nicotine dependence 
In smoking cessation, the treatment decisions are based on knowledge of a per-
son’s ND strength. There are several methods to determine strength of ND; for 
example, by asking how soon after waking up a person smokes their first ciga-
rette. As a measure, time to first cigarette (TTFC) has great validity (Baker et 
al., 2007). Quicker TTFC means higher dependence. Another option is the Hea-
viness of Smoking index (HSI), which has two items – “time to first cigarette 
upon waking” and “number of cigarettes smoked per day”. This approach is 
used for example in cases of limited time and resources (Heatherton et al., 
1991). 
The most widely used instrument to measure ND is Fagerström Test for Nico-
tine Dependence (FTND) (Heatherton et al., 1991). The test was first introduced 
as Fagerström Tolerance Questionnaire in 1978 and consisted of eight items. In 
1991, the test was revised by the author Karl-Olov Fagerström and his co-authors. 
From the questionnaire, items concerning inhalation and nicotine rating were 
removed. The revised version had six items (Heatherton et al., 1991): 
 
Questions Answers Points 
1. How soon after you wake up do you 
smoke your first cigarette? 
Within 5 minutes  3 
6–30 minutes 2 
31–60 minutes 1 
After 60 minutes 0 
2. Do you find it difficult to refrain 
from smoking in the places where it 
is forbidden e.g. in church, at the 
library, in cinema, etc.?  
Yes 1 
No 0 
3. Which cigarette would you hate most 
to give up?  
The first one in the 
morning  
1 
All others 0 
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Questions Answers Points 
4. How many cigarettes/day do you 
smoke on average? 
10 or less 0 
11–20 1 
21–30 2 
31 or more 3 
5. Do you smoke more frequently during 
the first hours after waking than during 
the rest of the day?  
Yes 1 
No 0 
6. Do you smoke if you are so ill that you 





Based on the answers to questions, a score is calculated. However, there are 
different scoring systems in use, based on whether 0 points can be assigned or 
not. The above-mentioned scale is provided by the author of the FTND. There, 
the result in the range of 0–10 can be calculated. Based on the score, ND 
strength is determined.  
In studies, different cut-off points and categorizations are in use to determine 
ND strength. For example, ND has been determined as low when FTND score 
is in range 1–4 (Layoun et al., 2017) or 0–5 (Lim et al., 2012). Similarly, high 
dependence was determined for scores ≥5 (Layoun et al., 2017), above 6 (Papa-
dopoulos et al., 2008) or 7 and more (Caponnetto & Polosa, 2008). The present 
study uses cut-off points as follows: low for the score ≤3, moderate for the score 
4–6, high for the score ≥7 (Fagerström et al., 2012).  
The higher the ND score, the higher the dependence. Higher ND score indi-
cates lower abstinence rates (Fagerström et al., 2012) and more intense with-
drawal symptoms (Difranza et al., 2012). 
 
 
2.4. Smoking prevalence globally and in Estonia 
According to WHO data, smoking prevalence in the world has declined during 
the last decades. In 2007, globally about 31% of men and 11% of women were 
current cigarette smokers. In 2018, the prevalence was 26% among men and 9% 
among women. 
Currently, smoking prevalence tends to be higher in South-East Asian and 
Western Pacific regions, where in some cases, up to 75% of men and 50% of 
women smoke. In Europe, current cigarette smoking prevalence is highest in 
Eastern and some Western European countries, reaching almost 50% among 
men and about 35% among women. 
Looking at the Estonia’s neighbouring countries, in Finland, in 2007, 25% of 
men and 19% of women were current smokers (Figure 1). In 2018, the pre-
valence of current smoking was 19% among men and 16% among women. In 
Latvia, among men, current smoking was 48% in 2007 and 44% in 2018 and 




Figure 1. Age-standardized for WHO standard population (Ahmad et al., 2001) pre-
valence of current cigarette smoking in Estonia (EE), Latvia (LV), Lithuania (LT), 
Finland (FI) and Sweden (SE), 2007–2018 (WHO, 2020b). 
 
 
In Estonia, adults smoking behaviour data has been collected since 1990. 
Among 16–64-year-olds, in 1990, 44% of men and 15% of women were daily 
smokers (Figure 2). Smoking prevalence was the highest in 1994, when 50% of 
men and 21% of women were daily smokers. Since 2006, the prevalence of 
daily smoking has declined steadily from 48% among men and 21% among 





Figure 2. Daily smoking prevalence in Estonia among 16–64-year old adults, 1990–
2018 (NIHD, 2019b). 
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2.5. Smoking among physicians 
2.5.1. Physicians’ tobacco epidemic 
The trends of smoking among physicians could indicate smoking tendencies 
among the general population. According to the physicians’ tobacco epidemic 
model, physicians take up smoking earlier than the general population (Figure 
3) (Davis, 1993). This has been, on one hand, related to the hazards of smoking 
not yet being evident in the society, and on the other hand, to the higher income 
of physicians that allows them to spend on tobacco. This is called the immature 
phase in the model. After some time, when the health risks of smoking become 
more apparent, the physicians’ smoking prevalence begins to decline. This 
could take several years, as the smoking-attributable diseases could take time to 
develop. At this time, smoking among the general population is still increasing. 
The second phase of the model, the mature phase, describes the situation where 
physicians smoke less than the general population. Sometime after that, 
smoking among general population will decrease, as well. However, smoking 





Figure 3. Physicians' tobacco epidemic model, adapted from Davis, 1993.  
 
 
According to the physicians’ tobacco epidemic model, countries like Italy, the 
Philippines, and Portugal are considered immature (La Vecchia et al., 2000; 
Ravara et al., 2014; WHO, 1997, 2015). Countries in the second phase can be 
described as mature and this includes, for example, Finland, Denmark but also 
Estonia (Pärna et al., 2005d; Smith & Leggat, 2007). 
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2.5.2. Smoking among physicians globally and in Estonia 
Among physicians worldwide, smoking prevalence has declined. The longest 
study exploring smoking among physicians is the British male doctors’ smoking 
survey that was first started in 1951 (Doll et al., 1994). According to the results, 
in 1951–1991 smoking prevalence among that population declined from 62% to 
18% (Doll et al., 1994). 
Among physicians in Australia, in the 1960s about a third of physicians 
smoked, but in the late 1990s, only 3% smoked (Smith & Leggat, 2008). The 
lowest prevalence of smoking among physicians has been reported from the 
United States of America, where in 2000, 2% of physicians smoked (Smith & 
Leggat, 2007). In 2001, in Denmark, 15% of physicians smoked (Smith & Leg-
gat, 2007) and in Finland, at the beginning of the 2000s, daily smoking pre-
valence was 7% among men and 4% among women (Barengo et al., 2004). 
In developed countries, there are also some exceptions in terms of physi-
cians’ smoking, with the prevalence being remarkably higher than elsewhere. 
For example, in Japan in 2000, 27% of men and 7% of women were smokers. 
By 2009, prevalence of current smoking among physicians in Japan was 16% 
among men and 5% among women (Smith & Wada, 2013).   
In developing countries, for example in Mexico, at the beginning of 1990s, 
61% of physicians smoked. In 2000, the prevalence was about three times lower 
(21% of men and 16% of women were daily smokers) (Abdullah et al., 2014). 
In the Philippines, from 1987 to 2009, smoking among physicians decreased 
from 63% (among men only) to 28% (among both men and women) (WHO, 
1997) (Adraneda, 2015). 
In Estonia, smoking among physicians has declined since 1978. In 1978, 
42% of men and 20% of women were current smokers (Väärt et al., 1979). In 
1982, 42% of men and 15% of women were current smokers (Rahu & Raud-
sepp, 1986). By 2002, the prevalence of current smoking had declined to 26% 
among men and 11% among women (Pärna et al., 2005a). As smoking among 
physicians was lower than among the general population, Estonia was a mature 
country in terms of the tobacco epidemic. 
 
 
2.6. Attitudes towards smoking behaviour 
2.6.1. Attitudes towards smoking 
Physicians are regarded as people from whom smokers would accept advice on 
smoking cessation (WHO, 2005). In former studies among Italian physicians 
specialising in public health, 80% considered health professionals as behaviou-
ral models for patients, and 97% affirmed that health professionals have a role 
in giving advice or information about smoking cessation (La Torre et al., 2014). 
In Serbia, 61% of physicians agreed that healthcare professionals serve as role 
models for their patients and for the public (Stojanovic et al., 2013). In Finland, 
in 2001, about 80% of non-smoking physicians agreed that setting a good 
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example is important. Compared to Finnish physicians, Estonian physicians 
were less conscious of their role as healthy lifestyle exemplars in 2002 (Pärna et 
al., 2005a).  
Physicians who smoke, are less likely to agree that smoking is harmful (Pipe 
et al., 2009). Furthermore, they underestimate the effects of tobacco smoke on 
health, and this influences their practice (Meshefedjian et al., 2010; Pärna et al., 
2005a; Willaing et al., 2003). 
 
 
2.6.2. Addressing patients’ smoking 
Theoretical framework 
Physicians should screen all patients for tobacco use, offer advice to quit, and 
provide assistance and follow-up to patients who are tobacco users (CDC, 
2013). In assisting patients to quit smoking, the World Health Organization re-
commends using the “5 A’s” intervention strategy which was developed for 
smoking cessation and provides a model that guides the physician through the 
process of helping a patient quit tobacco. The model involves 5 brief inter-
ventions  (WHO, 2001) (WHO, 2014):  
– Ask (systematically identify all tobacco users at every visit, record smoking 
status, keep the record up to date); 
– Advise (persuade all tobacco users that they need to quit by advising 
smokers of the benefit of stopping in a personalised and appropriate manner 
(this may include linking the advice to their clinical condition); 
– Assess (assess motivation to stop and readiness to make a quit attempt); 
– Assist (help the patient with a quit plan including the offer of support, re-
commendation to use NRT or bupropion and accurate information and 
advice about them, referral to a specialist cessation service if necessary); 
– Arrange (arrange follow up if possible by scheduling follow-up contacts or a 
referral to specialist support). 
 
Data on addressing patients’ smoking 
According to the “5 A’s” model, the first step would be to ask patients about 
their smoking habits. However, prevalence of addressing patients’ smoking vary 
across countries, and physicians do not know their patients’ smoking status 
(Bryant et al., 2015). For example, in the Netherlands 62%, and in the United 
Kingdom 98% of general practitioners asked all new patients about their 
smoking status and did so only during the first visit. Fewer physicians addressed 
patient smoking routinely (28% of physicians in Belgium, 63% in the United 
Kingdom) (Stead et al., 2009). In Finland, in the beginning of 2000s, about 80% 
of physicians asked their patients about smoking at least once during a week. 
Among physicians in Estonia, the result was similar (Pärna et al., 2005a).  
Smoking physicians are less likely to ask patients about smoking, when 
compared to non-smoking colleagues (Garfinkel, 1976; Kawakami et al., 1997; 
Mughal et al., 2018; Pipe et al., 2009; Puska et al., 2005; Reile & Pärna, 2018; 
Stead et al., 2009; Tang et al., 2013). 
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Finding smoking cessation to be an important task and acknowledging that it 
is a part of a physician’s job, feeling comfortable about giving smoking cessa-
tion related information and believing their actions to be effective, increases the 
chances of a physician addressing patients’ smoking. On the other hand, per-
ceiving the discussion of smoking as harmful to the professional relationship, 
wishing not to invade a patient’s privacy, having previous unpleasant expe-
rience, but also low confidence in one’s own knowledge, decrease the probabi-
lity that a doctor addresses patients’ smoking habits. (Alateeq et al., 2016; Jradi 
et al., 2015; Stead et al., 2009).  
A systematic review conducted among primary care physicians showed that 
38% did not believe that discussing smoking would be effective, 18% had un-
pleasant personal experiences related to the task, 22% had no confidence in 
their own ability and 16% had no confidence in their knowledge. Few (5% or 
less) physicians expressed that discussing smoking with patients would be an 
intrusion of privacy (interfering with patients’ personal choice) and that dis-
cussing smoking is not justified (Vogt et al., 2005). 
In addressing patients’ smoking, in addition to personal attitudes, other fac-
tors have been shown to play a role. For example, physician’s higher age has 
been associated with higher odds of asking about patients’ smoking (Mughal et 
al., 2018). When looking at medical specialty, general practitioners were more 
likely to address patients’ smoking habits (Meijer et al., 2019). 
The contextual factors related to addressing patients’ smoking habits are 
time, training and reimbursement (Stead et al., 2009). Lack of time is the most 
reported barrier to delivering smoking cessation care (Jradi et al., 2015; Meijer et 
al., 2019; Vogt et al., 2005) and has been found to be so among physicians in 
Estonia as well (Pärna et al., 2005a). Having sufficient training affects physicians’ 
confidence in their skills, which then again leads to more actively addressing 
patients’ smoking (Alateeq et al., 2016; Meijer et al., 2019) (Stead et al., 2009). 
 
 
2.6.3. Desire to quit smoking among physicians 
Theoretical framework 
Quitting smoking as a behaviour change can demonstrate distinguishable stages, 
like those in the states-of-change model (Prochaska et al., 1993): 
– pre-contemplation (no intention to change in the near future); 
– contemplation (awareness of the problem, seriously thinking about over-
coming it but have not yet made a commitment to take action); 
– preparation (intending to take action, unsuccessful attempts in the past year; 
small behavioural changes); 
– action (behaviour, experiences, environment modification, considerable 
commitment of time and energy); 
– maintenance (preventing relapse, consolidating gains). 
Intention or desire to quit precedes a concrete action like a quit attempt.  
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Data on desire to quit smoking 
Greater intention to quit predicts success of a quit attempt (Hyland, 2006). The 
intention to quit smoking has been associated with several factors. For example, 
it has been shown to be higher among younger people (Marques-Vidal et al., 
2011), among people with higher ND, among those with a higher number (6 and 
more) of previous quit attempts and among people with higher alcohol con-
sumption (Marques-Vidal et al., 2011; Myung et al., 2012). Higher annual in-
come and higher education was also associated with having an intention to quit 
(Myung et al., 2012). 
Among physicians, in Poland in 2004 about 60% of smoking physicians 
wished to quit, but in the Czech Republic in 1995 about 75% of smoking physi-
cians had an intention to quit (Abdullah et al., 2014). 
 
 
2.7. Nicotine dependence among physicians and  
the general population 
Quitting smoking could prove difficult due to ND (DiFranza et al., 2002; Hy-
land et al., 2004). Nicotine acts on nicotinic cholinergic receptors in the brain to 
trigger the release of dopamine and other neurotransmitters. Repeated exposure 
to nicotine results in the development of tolerance and this leads to smoking 
more often to maintain enhancement of mood and prevention of withdrawal 
symptoms like irritability, anxiety, depressed mood, difficulty in concentrating, 
increased appetite, insomnia (Benowitz, 2010; Chawla & Garrison, 2018). As 
the withdrawal symptoms are unpleasant for the smoker, specific moods and 
situations are associated with the rewarding effects of nicotine. This reflects the 
behavioural component of ND and is often the trigger for relapse (Benowitz, 
2010).  
ND is also associated with factors like the age of tobacco uptake. The earlier 
the age of initiating smoking, the higher are the chances that a person will be-
come a smoker (Breslau et al., 1993). In addition, desire to quit, more previous 
quit attempts, and smoking relapses have been found to be associated with 
higher ND (Zhou et al., 2009). 
Data concerning nicotine dependence among physicians is scarce. The avail-
able results show that low ND tends to be more prevalent among physicians; for 
example, in Germany, where in 2018, 65% of physicians had low dependence 
(HSI score ≤2) (Pförringer et al., 2018) and in Spain, in 2015, where about 82% 
of physicians who smoked had low ND (FTND score ≤3) (Juárez-Jiménez et al., 
2015). However, in Turkey in 2014, 46% of smoking physicians had low ND 
(FTND score ≤3) (Baltaci et al., 2014). 
According to the studies exploring ND in the general population, the lowest 
scores (2.8 points) have been in Germany (in 1997) and Norway (in 1995), but 
the highest average scores of 4.6 points were in Sweden (around 2000) and 
USA (1990s) (Fagerström & Furberg, 2008). 
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2.8. Smoking-related policies in Estonia 
During the last decades, the tobacco policy in Estonia has progressed well and 
follows international developments. However, in terms of smoking prevention, 
policies and movements became notably more active at the beginning of the 
2000s. Figure 4 illustrates main milestones of smoking-related policies in 
Estonia. In 2005, Estonia ratified the World Health Organization Framework 
Convention on Tobacco Control (FCTC) (WHO, 2005). The first version of the 
current Tobacco Act was adopted in 2005 (Tobacco Act, 2005) and has been 
complemented in most years since. The tobacco policy in Estonia also relies on 
the “Green Paper on tobacco policy” (Ministry of Social Affairs, 2014) and the 
“National Health Plan” (Ministry of Social Affairs, 2012).  
The Tobacco Act (2005) defines what is a tobacco product and what are the 
related products. It describes regulations for handling the products, prohibitions, 
and restrictions on consumption of tobacco products and products related to 
tobacco products. 
In Estonia, smoking is prohibited for example on the premises of children’s 
welfare institutions and their designated territories, in spaces intended for 
sports. In the catering establishments, smoking is prohibited since 2005. On  
the premises of enterprises providing health services, smoking in restricted, 
meaning that smoking is allowed only in a designated smoking room.  
Currently in Estonia most of the national campaigns addressing the promo-
tion of smoking cessation and decrease in tobacco consumption are organized 
by the National Institute for Health Development (NIHD) which was created in 
2004. The institute collects and provides data related to health behaviour of the 
Estonian population but also manages the websites on tobacco information 
(tubakainfo.ee) and general health information (terviseinfo.ee), which are valu-
able resources for the public and for the organizations involved in health pro-
motion.  
NIHD also provides information on creating tobacco-free workplaces. 
Estonia joined the International Network of Health Promoting Hospitals and 
Health Services in 1999 and currently, most of the hospitals have joined the 
network. Furthermore, one of the biggest hospitals, Tartu University Hospital, 
has achieved the Gold Forum membership, which means that a systematic 
tobacco cessation program, health promotion program, tobacco-free healthcare 
environment, and tobacco-free culture among healthcare staff had to be 
achieved. 
The first clinic offering smoking cessation treatment in Estonia opened in 
1999. To make the services available to the population, the system of coun-
selling services was established in 2005 as a measure to reduce cardiovascular 
diseases. In the same year, the network of smoking cessation counselling offices 
was created, based on the network of health promoting hospitals, covering all 





Figure 4. Milestones in smoking-related policies in Estonia, 1999–2019. 
 
 
Until 2018, the NIHD was responsible for smoking cessation services, but in 
2019, smoking cessation services were added to the national health benefits list. 
This means that national health insurance covers smoking cessation counselling 
for the insured persons (more than 90% of the population of Estonia is covered 
by national health insurance), whereas before, the services were financed 
through other means, for example health promotion projects. 
In 2010, the NIHD published the methodological guidelines for the smoking 
cessation service and in 2012, the guidelines for family physicians were pub-
lished (Ani & Ingerainen, 2012; NIHD, 2010). Currently, the national clinical 
guidelines for smoking cessation services are in development under the coordi-
nation of the Estonian Health Insurance Fund and the University of Tartu. 
Smoking cessation counselling services are free of charge for the patients in 
Estonia, but pharmacological treatment for smoking cessation is currently not 
reimbursed. However, it has been suggested that a reimbursement rate of at least 
50% should be introduced (Alloja et al., 2019). 
 
 
2.9. Brief summary 
In conclusion, based on the worldwide literature, knowledge of smoking beha-
viour of the physicians is important as physicians can be considered role models 
in the society but also because they have the opportunity to influence smoking 
behaviour among the population. 
Smoking survey among physicians in Estonia is the longest regular health 
survey in the country with the existing database for the years from 1982 to 
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2014. Until now, in-depth analysis of smoking among physicians over the study 
years has not been carried out. The present study attempts to fill this gap.   
The present study provides the opportunity to gain insight into the smoking 
trends among physicians thus allowing to compare Estonia with the other 
countries. The study investigates long-term patterns of attitudes towards 
smoking behaviour as well as readiness to address patients’ smoking to ensure 
evidence-based continuous development of physicians’ training in prevention 
and decreasing of smoking. Also, the study provides for the first time an over-
view of ND among daily smoking physicians in Estonia to gain understanding 
of possible obstacles in smoking cessation among physicians and to further 




3. AIMS OF THE RESEARCH 
The general objective of the research was to provide evidence on smoking, 
attitudes towards smoking behaviour, and nicotine dependence among physi-
cians in Estonia in 1982–2014.  
 
The specific objectives were:  
1. to describe trends in smoking among physicians in 1982–2014 (Paper I); 
2. to analyse the views of physicians about the role of smoking in smoking-
related diseases in 1982–2014 (Paper II); 
3. to explore attitudes towards smoking behaviour in 2002 and 2014 (Paper 
III); 
4. to describe frequency of addressing patients’ smoking in 2002 and 2014 and 
to analyse factors related to addressing patients’ smoking habits (Paper IV); 
5. to explore factors associated with desire to quit smoking among currently 
smoking physicians in 2002 and 2014 (Paper V); 
6. to describe nicotine dependence and to analyse association between nicotine 
dependence and factors related to smoking cessation among daily smoking 
physicians in Estonia in 2014 (Paper VI). 
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4. MATERIALS AND METHODS 
4.1. Data collection 
The data for the research was drawn from the Estonian physicians’ smoking 
surveys in 1982, 2002 and 2014. All surveys were cross-sectional and relied on 
self-reported data. Initially, all practicing physicians in Estonia were included in 
the sample. Every survey year, different databases were used as a data source. 
Although there was a health care professionals’ registry already in 2002, when 
the study sample was being compiled, the registry was undergoing renewal and 
was not available.  
Table 1 describes the data collection process, initial sample sizes (number of 
physicians in the according registries), number of respondents (physicians who 
sent back the questionnaires), crude and corrected response rates of the surveys. 
The questionnaires were mailed to physicians’ workplace addresses in the 
first two study years and to home addresses in 2014. There is no information on 
reminder letters in 1982, but in 2002, a reminder with a copy of the question-
naire was sent to non-respondents 4−6 weeks after the initial questionnaire. In 
2014, after 4 weeks, a reminder letter was sent to non-respondents, and after 8 
weeks, all the study materials were sent again. 
The corrected response rate (excluding the physicians who had retired, had 
an incorrect address, had left Estonia or had died) was 67.8% in 2002 and 
53.1% in 2014. For 1982, corrected response rate is not available. 
The survey questionnaire in 1982 (Appendix I) included 17 questions re-
garding demographics, smoking status, and attribution of the causal role of 
smoking in smoking-related diseases. The questionnaire used in the 2002 survey 
(Appendix II) was based on a validated questionnaire developed by the World 
Health Organization (WHO, 1998). The questionnaire was translated from 
English using back and forth translation and was adapted according to the Esto-
nian healthcare system. The questions used in 1982 were kept in similar form in 
2002 to ensure comparability. In 2002, questions were added to determine 
desire to quit smoking and attitudes towards smoking. In 2014, the question-
naire (Appendix III) was further supplemented by the six-item Fagerström Test 
for Nicotine Dependence. The questionnaires asked to name tobacco products 
used like cigarettes, cigars, pipes, hand-rolled cigarettes. The present study 
explored cigarette smoking.  
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Table 1. Data collection in physicians’ smoking surveys, 1982–2014 
Characteristics 1982 2002 2014 
Data source 
The database of 
Ministry of 
education 
The database of 
Estonian Health 
Insurance Fund 
The database of 




mailed Work address Work address Home address 
Reminder – 
After 4−6 weeks 
(reminder letter and 
questionnaire) 
After 4 weeks 
(letter) and 8 weeks 
(reminder letter and 
questionnaire) 
Initial sample (n) 4704 4140 5666 
Respondents (n) 3792 (901 men, 2891 women) 
2747 (471 men, 
2276 women) 
2892 (529 men, 
2363 women) 
Crude response 
rate (%) 80.7 66.3 52.0 
Corrected* 
response rate (%) – 67.8 53.1 
Papers I, II I−V I−VI 
* Excluding the physicians who were unavailable, had an incorrect address, had left 
Estonia, or had died. 
 
 
4.2. Study sample and variables  
Trends in smoking behaviour (Paper I) 
The study sample consisted of physicians who answered the question con-
cerning smoking status (n=3786 in 1982, n=2735 in 2002, n=2902 in 2014). 
 
The main outcome variable 
− smoking status: current (daily, occasional), past, never 
 
Background variables 
− age: ≤34, 35–44, 45–54, 55–64, ≥65 
− gender: men, women 
 
Smoking-related variable 
− age of initiation of smoking (measured in full years). 
 
Views on the causal role of smoking smoking-related diseases (Paper II) 
The study sample consisted of physicians who answered to the questions con-
cerning smoking status and to questions regarding causal role of smoking in 
three smoking-related diseases (ischaemic heart disease (IHD), lung cancer, and 
chronic bronchitis) (n=3504 in 1982, n=2735 in 2002, n=2902 in 2014). 
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The main outcome variable 
− agreement with the causal role of smoking in three smoking related diseases: 
agree (a major cause, one of the causes) and disagree (probably not a cause, 
not a cause, cannot say) 
 
Smoking-related variable 
− smoking status: current (daily, occasional), past, never 
 
Background variables:  
− age: ≤34, 35–44, 45–54, 55–64, ≥65 
− gender: men, women 
− ethnicity: Estonian, non-Estonian 
− study year: 1982, 2002, 2014. 
 
Physicians’ attitudes towards smoking (Paper III) 
The study sample involved physicians who were under 65 years of age and who 
answered the questions regarding smoking status and questions concerning atti-
tudes towards smoking (n=2539 in 2002 and n=2338 in 2014).  
 
The main outcome variables 
− agreement with the seven statements concerning attitudes towards smoking: 
1) smoking is very harmful to health 
2) it is important to reduce smoking among the population 
3) to stop smoking is very hard for many people, so it is better for their 
health to simply continue smoking 
4) smoking does not damage my health as long as I follow a healthy lifestyle 
in other fields 
5) as many people have smoked for their whole lives until old age and not 
become ill, smoking is not as dangerous as experts declare 
6) to smoke or not to smoke, that is my personal choice 
7) smoking is only dangerous to my health if I smoke more than 10 ciga-
rettes a day 
− smoking status: current (daily, occasional), past, never. 
 
Background variables 
− age: <45, 45–64 
− gender: men, women 
− ethnicity: Estonian, non-Estonian 
− place of residence: Tallinn (capital of Estonia), other city, and other (non-
urban) settlement 
− medical specialty: family physician, specialist doctor, dentist 




Addressing patients’ smoking (Paper IV) 
The study sample consisted of physicians who were under 65 years of age and 
who answered the question regarding addressing patients’ smoking habits 
(n=2488 in 2002 and n=1791 in 2014). 
 
The main outcome variable 
− addressing patients’ smoking in last 7 days: never, at least once (sometimes, 
every other time, often, always) 
 
Variables regarding attitudes towards smoking 
− agreement (yes, no, cannot say) that it is the physicians’ responsibility to 
convince people to stop smoking 
− agreement (yes, no, cannot say) that physicians should have smoking related 
materials to give out to patients if needed 
− agreement (yes, no, cannot say) that my present knowledge is sufficient to 
advise a patient who wishes to stop smoking 
− agreement (yes, no, cannot say) that smoking prevention should form part of 
the normal training of health professionals 
− agreement (yes, no) that lack of habit is a barrier to addressing patients’ 
smoking 
− agreement (yes, no) that lack of time is a barrier to addressing patients’ 
smoking 
− agreement (yes, no) that wish to respect patient’s privacy is a barrier to 
addressing patients’ smoking 
 
Smoking related variable 
− smoking status: current (daily, occasional), past, never 
 
Background variables 
− age: measured in full years 
− gender: men, women 
− ethnicity: Estonian, non-Estonian 
− medical specialty: family physician, specialist doctor, dentist 
− study year: 2002, 2014.  
 
 Desire to quit (Paper V) 
The study sample consisted of physicians who were under 65 years of age. The 
study included currently smoking physicians who answered the question 
regarding desire to quit smoking (n=322 in 2002, n=189 in 2014). 
 
The main outcome variable 
− desire to quit smoking: yes, no, cannot say  
 
Smoking related variables 
− smoking status: daily, occasional 
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− concern about harms of smoking: yes, no 
− number of previous quit attempts: none, 1–2, 3–4, 5 or more 
− stress as main reason to restart smoking: yes, no 
− motivation to quit smoking (one answer from the list, or reason provided by 
the respondent): personal health problems, material stimulus, wish to set a 
good example, other reasons (social pressure, family related issues, becoming 
a parent etc.) 
 
Background variables 
− gender: men, women 
− age: ≤34, 35–44, 45–54, 55–64  
− ethnicity: Estonian, non-Estonian 
− place of residence: Tallinn, other city, non-urban 
− medical specialty: family physician, specialist doctor, dentist 
− study year: 2002, 2014.  
 
Nicotine dependence (Paper VI) 
The study included daily smoking physicians who answered questions regarding 
smoking status and the FTND questions (n=171 in 2014).  
 
The main outcome variable 
− ND: low, at-least-moderate (moderate, high) ND  
 
Smoking related variables 
− age of initiation of smoking 
− desire to quit: yes, no, cannot say 
− main motives to quit smoking (one answer from the list, or provided by the 
respondent): personal health problems, wish to set a good example, other 
reasons (material stimulus, social pressure, family related issues, becoming a 
parent etc.), cannot say 
− number of previous quit attempts: none, 1–2, 3–3, 5 or more 
− stress as the main reason to restart smoking: yes, no 
 
Background variables 
− gender: men, women 
− age: measured in full years 
− ethnicity: Estonian, non-Estonian 




4.3. Statistical analysis 
Trends in smoking behaviour (Paper I) 
Prevalence of current smoking with corresponding 95% confidence interval (CI) 
was determined. Age-standardized smoking prevalence rate with the correspon-
ding 95% CI was calculated using European standard population (Ahmad et al., 
2001). Mean age of respondents with standard deviation, minimum and maxi-
mum value, and mean age of smoking initiation with 95% CI were calculated. 
To determine significant changes in smoking over time, a non-parametric test 
for trend was used. 
 
Views on the causal role of smoking (Paper II) 
Mean age (with SD, minimum and maximum value) and distribution of respon-
dents by age group and ethnicity was calculated. Age-standardized smoking 
prevalence rate with the corresponding 95% CI was calculated using European 
standard population (Ahmad et al., 2001). Prevalence of agreement/disagree-
ment with the statements concerning smoking as a reason for IHD, lung cancer 
and chronic bronchitis was determined. 
To test for associations between agreement with a causal role of smoking in 
IHD, lung cancer, and chronic bronchitis, and explanatory variables, logistic 
regression analysis was conducted. Fully adjusted odds ratios with 95% CI were 
calculated.  
 
Physicians’ attitudes towards smoking (Paper III) 
Age-standardised prevalence of smoking with corresponding 95% CIs was 
calculated using European standard population (Ahmad et al., 2001). Mean age 
(with SD) of respondents was calculated. Distribution (%) of respondents by 
agreement with the statements concerning attitudes towards smoking and by 
explanatory variables was calculated. To test for differences in attitudes towards 
smoking and in explanatory variables between 2002 and 2014, the chi-squared 
test was used.  
To determine association of attitudes towards smoking with smoking status 
and explanatory variables, logistic regression models were used. Fully adjusted 
odds ratios with 95% CI were calculated.  
 
Addressing patients’ smoking (Paper IV) 
Mean age (with SD) of respondents was calculated. To test for differences 
between mean ages, a t-test was used. Distribution of the sample by explanatory 
variables was determined. Age-standardized prevalence of addressing patients’ 
smoking habits was calculated along with 95% CI using European standard 
population (Ahmad et al., 2001).  
To analyse association between addressing patients’ smoking habits (at least 
once during last 7 days vs never) and explanatory variables, a fully adjusted 
logistic regression model was calculated. Fully adjusted odds ratios with 95% 
CI were calculated. 
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Desire to quit (Paper V) 
Distributions of physicians by desire to quit smoking, smoking frequency, 
factors related to smoking behaviour and background characteristics were calcu-
lated along with the mean age of respondents and standard deviation.  
Logistic regression analysis was used to determine association between de-
sire to quit smoking and factors related to smoking behaviour. Two models 
were performed: Model I (adjusted for gender, age, and year) and Model II (ad-
justed for all explanatory variables). Fully adjusted odds ratios with 95% CI 
were calculated. 
 
Nicotine dependence (Paper VI) 
Mean age of respondents, mean age of smoking initiation and mean FTND 
score were calculated along with standard deviations (SD). ND was determined 
based on FTND score (low for the score ≤3, moderate for the score 4–6, high 
for the score ≥7). To test for differences between men and women in the distri-
bution of FTND results and of ND, the Fisher exact test was used. To test for 
differences between the mean age of smoking initiation among respondents with 
low and at-least-moderate ND, a t-test was used. To compensate for response-
bias, post-stratification weights were used based on gender and 5-year age 
groups of the sample of physicians in Estonia (Raag & Pärna, 2018) 
To determine association of ND (at-least-moderate vs low) with factors 
related to smoking cessation, a logistic regression model was used. The data for 
men and women was pooled for the analysis, as there was no significant diffe-
rence between men and women in ND score. Fully adjusted odds ratios with 
95% CI were calculated. 




4.4. Ethics and consent 
The surveys in 2002 and 2014 were approved by the Research Ethics Commit-
tee of the University of Tartu (decisions no. 87/1 and 235/T-12, respectively). 
With the survey questionnaire, recipients were sent a cover letter including a 
description of the study design and how the collected data would be used. The 
letter explained that participation in the study would be considered to constitute 
consent. Additional written consent was not obtained. Ethical approval had not 






Figure 5. Age-standardized (for European population, by Ahmad et al., 2001) pre-
valence of current smoking among physicians in Estonia, 1982–2014. 
  
5. RESULTS 
5.1. Trends in smoking (Paper I) 
The mean age of smoking initiation was 20.4 in 1982 and 19.3 in 2014 for men 
and 24.5 in 1982 and 20.4 in 2014 for women (Table 2). Compared to 1982, the 
mean age of smoking initiation was significantly lower in 2014 among women.  
 
 
Table 2. The mean age and 95% confidence interval for smoking initiation among 
currently smoking physicians by gender and study year 
Study year Men Women Mean age 95% CI Mean age 95% CI 
1982 20.4 20.0–20.8 24.5 24.0–25.0 
2002 19.9 18.9–20.8 22.3 21.5–23.0 
2014 19.3 18.1–20.5 20.4 19.7–21.1 
 
 
Figure 5 presents the age-standardized (for European population by Ahmad et 
al., 2001) prevalence of current smoking in 1982, 2002 and 2014. There was a 
significant decrease of current smoking among both men and women (p<0.001 
for trends). Among men, the prevalence of current smoking was 39.7% in 1982 
and 14.3% in 2014. Among women, the prevalence of current smoking was 
12.2% in 1982 and 5.2% in 2014.  
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Age-standardized prevalence of daily smoking was 38.3% in 1982, 15.0% in 
2002 and 11.7% in 2014 among men and 10.3%, 4.7% and 3.9%, respectively, 
among women. Age-standardized prevalence of occasional smoking was 1.4% in 
1982, 5.9% in 2002 and 2.6% in 2014 among men, 1.9%, 3.3% and 1.2%, respec-
tively, among women. Age-standardized prevalence of past smoking among men 
increased from 24.2% in 1982 to 28.3% in 2002, and then decreased to 25.0% by 
2014. Among women the age-standardized prevalence of past smoking increased 
from 10.6% in 1982 to 16.3% in 2014. From 1982 to 2014, age-standardized 
prevalence of physicians who had never smoked increased from 33.3% to 50.8% 
among men and from 74.4% to 78.5% among women. 
The biggest decrease of current smoking among men and women was in 
those aged ≤34 (55.2% and 16.7% for men, 16.7% and 2.8% for women, res-
pectively) and in the age group 35–44 (47.1% and 8.3% for men, 19.5% and 
5.1% for women, respectively) (p < 0.001 for trends) (Figure 6).  
Current smoking decreased significantly among 45–54-year-old and 55–64-
year-old men (p=0.001 and p=0.006, respectively), but increased among men in 
the oldest age group (p=0.429). While in 1982 and 2002 the highest prevalence 
of current smoking among men was among ≤34-year-old (55.2% and 30.7%, 
respectively) followed by those aged 35–44 (47.1%) in 1982 and those aged 45– 
54 (28.0%) in 2002, then in 2014 the highest prevalence was in those aged 55–
64 (19.8%), followed by those aged 45–54 (17.3%) and ≤34 (16.7%). 
Among women, current smoking decreased in the 45–54 age group (p=0.009), 
was stable among 55–64- year-olds (p=0.751), and increased in the oldest age 
group (p=0.156). While in 1982 and 2002 the highest prevalence of current 
smoking among women was in the age group 35–44 (19.5% and 12.3%, respec-
tively) followed by the age group ≤34 (16.7%) in 1982 and 45–54 (10.7%) in 
2002, then in 2014 the highest prevalence was in thein age group 55–64 (8.9%), 
followed by age groups 45– 54 (7.1%) and ≥65 (6.4%).  
 
 
Figure 6. Prevalence of current smoking (%) by gender and age group among physi-
cians in Estonia, 1982–2014. 
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5.2. Physicians’ attitudes towards smoking 
5.2.1. Physicians’ views on the causal role of smoking in 
smoking-related diseases (Paper II) 
The majority of physicians agreed that smoking is a major cause, or one of the 
causes of IHD, lung cancer, and chronic bronchitis (Table 3). The prevalence of 
agreement increased for all conditions. In 1982, the agreement was higher for 
chronic bronchitis but by 2014, prevalence of agreement was more than 98% for 
all the conditions.   
 
 
Table 3. Agreement (%) among physicians that smoking is a major cause or one of the 
causes in IHD, lung cancer, chronic bronchitis 
Smoking-related disease 1982 2002 2014 Men Women Men Women Men Women 
Ischaemic heart disease  84.7 84.1 96.6 96.3 98.5 98.0 
Lung cancer 89.8 88.6 98.3 99.1 98.8 99.2 
Chronic bronchitis 94.8 93.9 98.8 99.1 99.0 99.2 
  
 
In fully adjusted logistic regression models (Table 4):  
− agreement that smoking is a cause of IHD was significantly associated with 
ethnicity among men and women, and with smoking status and age among 
women (Model I); 
− agreement that smoking is a cause of lung cancer was significantly as-
sociated with smoking status among men and women, and with ethnicity 
among women only (Model II); 
− agreement that smoking is a cause of chronic bronchitis was significantly as-
sociated with ethnicity among men and women and with smoking status 
among women (Model III). 
For all the conditions, compared to 1982, agreement was significantly higher in 




Table 4. Agreement (vs disagreement) that smoking is the cause of IHD (Model I), lung 
cancer (Model II), chronic bronchitis (Model III) 
Characteristic 
Men Women 
OR* 95% CI OR* 95% CI 
Study year Model I: IHD 
2002 vs 1982 4.49 2.61–7.72 5.03  3.91–6.48 
2014 vs 1982 10.40 4.95–21.85 9.78  7.04–13.59 
Smoking status     
Past vs current 1.16 0.74–1.82 1.66  1.17–2.35 
Never vs current 1.43 0.95–2.15 1.63 1.28–2.08 
Age     
35–44 vs ≤34 0.96 0.60–1.53 0.96  0.74–1.25 
45–54 vs ≤34 1.26 0.76–2.08 0.72  0.56–0.94 
55–64 vs ≤34 1.01 0.58–1.76 0.70  0.52–0.96 
≥65 vs ≤34 1.00 0.46–2.15 0.56  0.35–0.89 
Ethnicity     
Estonian vs Non-Estonian 1.88 1.31–2.69 1.35  1.10–1.64 
Study year Model II: Lung cancer 
2002 vs 1982 5.72 2.72–12.05 12.91 8.27–20.15 
2014 vs 1982 7.70 3.25–18.27 16.54 10.06–27.17 
Smoking status     
Past vs current 1.90 1.09–3.32 2.29 1.55–3.38 
Never vs current 2.31 1.39–3.82 3.71 2.84–4.83 
Age     
35–44 vs ≤34 0.58 0.33–1.02 1.41 1.03–1.94 
45–54 vs ≤34 1.08 0.57–2.04 0.82 0.60–1.12 
55–64 vs ≤34 0.81 0.40–1.63 0.81 0.56–1.19 
≥65 vs ≤34 0.74 0.28–1.97 0.66 0.35–1.26 
Ethnicity     
Estonian vs Non-Estonian 1.49 0.96–2.30 1.42 1.11–1.82 
Study year Model III: Chronic bronchitis 
2002 vs 1982 3.95  1.65–9.46 6.26  3.95–9.91 
2014 vs 1982 5.05  1.91–13.33 8.23  4.89–13.84 
Smoking status     
Past vs current 1.38  0.69–2.76 1.68 4.30–10.36 
Never vs current 1.88  0.97–3.65 2.11 1.48–  3.01 
Age     
35–44 vs ≤34 0.43  0.19–0.96 1.14 0.75–1.73 
45–54 vs ≤34 0.72  0.29–1.76 0.74 0.50–1.10 
55–64 vs ≤34 0.51  0.20–1.32 0.69 0.43–1.10 
≥65 vs ≤34 0.53  0.15–1.88 0.80 0.36–1.77 
Ethnicity     
Estonian vs Non-Estonian 1.88  1.08–3.30 1.72 1.27–2.32 
* Model for each condition adjusted for study year, smoking status, age, ethnicity. 
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5.2.2. Physicians’ attitudes regarding  
patients’ smoking (Paper III) 
Compared to 2002, in 2014, the attitudes towards smoking were less favourable 
among both men and women. Prevalence of agreement that smoking is harmful 
to health and that it is important to reduce smoking among the population was 
higher in 2014 than in 2002. On the other hand, in 2014, agreement that to stop 
smoking is very hard for many people, so it is better for their health to continue 
smoking, that smoking does not damage health as long as otherwise healthy 
lifestyle is followed, that as many people have smoked for their whole lives 
until old age and not become ill, smoking is not as dangerous as experts declare, 
that smoking is a personal choice and that smoking is only dangerous if more 
than 10 cigarettes a day are smoked was lower than in 2002.  
 
According to fully adjusted logistic regression models (Table 5), in 2014 (vs 
2002):   
− physicians agreed significantly more that smoking is harmful, and it is 
important to reduce smoking among the population; 
− physicians agreed significantly less that to stop smoking is very hard for 
many people, so it is better for their health to simply continue smoking, and 
that smoking does not damage person’s health as long as they otherwise 
follow a healthy lifestyle; 
− among women only, the agreement that as many people have smoked for 
their whole lives until old age and not become ill, smoking is not as 
dangerous as experts declare, that to smoke is a personal choice, and that 
smoking is only dangerous to health if more than 10 cigarettes a day are 
smoked decreased significantly. 
Agreement with all the statements was associated with smoking status among 






Table 5. Association of physicians’ attitudes towards smoking (agreed vs disagreed) 
with study year and smoking status (OR, 95% CI) 
Statements Men Women OR* 95% CI OR* 95% CI 
Smoking is very harmful to health  
2014 vs 2002 2.13 1.51–3.01 2.81 2.35–3.36 
Smokers vs non-smokers 0.27 0.19–0.39 0.22 0.17–0.27 
It is important to reduce smoking among the population 
2014 vs 2002 3.86 1.69–8.80 2.96 1.75–5.03 
Smokers vs non-smokers 0.41 0.20–0.84 0.27 0.16–0.45 
To stop smoking is very hard for many people, so it is better for their health to simply 
continue smoking 
2014 vs 2002 0.48 0.32–0.72 0.62 0.52–0.74 
Smokers vs non-smokers 2.54 1.67–3.86 3.46 2.67–4.49 
Smoking does not damage my health as long as I follow a healthy lifestyle in other 
fields 
2014 vs 2002 0.43 0.23–0.79 0.48 0.36–0.65 
Smokers vs non-smokers 6.86 3.90–12.06 4.56 3.29–6.33 
As many people have smoked for their whole lives until old age and not become ill, 
smoking is not as dangerous as experts declare 
2014 vs 2002 0.96 0.63–1.47 0.72 0.59–0.87 
Smokers vs non-smokers 5.88 3.83–9.02 3.75 2.88–4.89 
To smoke or not to smoke, that is my personal choice 
2014 vs 2002 1.01 0.74–1.38 0.78 0.68–0.89 
Smokers vs non-smokers 5.87 3.70–9.30 4.59 3.47–6.08 
Smoking is only dangerous to my health if I smoke more than 10 cigarettes a day 
2014 vs 2002 0.60 0.36–1.00 0.51 0.39–0.69 
Smokers vs non-smokers 4.77 2.90–7.84 4.32 3.10–6.04 




5.2.3. Addressing patients’ smoking habits (Paper IV) 
The prevalence of addressing patients’ smoking every other time, often and 
always was higher in 2014 than in 2002 (Figure 7). In 2002, 15.1% of men and 
16.4% women never asked about their patients’ smoking habits but in 2014, the 
prevalence decreased to 10.6% and 10.1%, respectively. 
 
 




According to the adjusted logistic regression model (Table 6), addressing 
patients’ smoking habits was significantly associated with  
− agreeing that it is physicians’ responsibility to convince people to stop 
smoking 
− agreeing that physicians should have smoking-related hand-out materials 
− physicians’ age. 
Among women only, addressing patients smoking habits was significantly 
associated with 
− agreeing that their current knowledge is sufficient to advise patients who 
wish to quit 
− being unsure whether smoking prevention should be a part of normal 
training 
− agreeing that lack of time, lack of habit and wish to respect patients’ privacy 
is a barrier to addressing patients’ smoking. 
Women were significantly more likely to address patients’ smoking in 2014 
compared to 2002.  
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Table 6. Addressing patients’ smoking (yes vs no) among physicians in Estonia, 2002 
and 2014 
Variable Men Women OR* 95% CI OR* 95% CI 
It is the physicians’ responsibility to convince people to stop smoking 
Yes vs no 2.32 1.19–4.54 1.41 1.06–1.88 
Cannot say vs no 0.97 0.45–2.10 1.20 0.88–1.65 
Physicians should have smoking related materials to give out to patients if needed 
Yes vs no 2.17 1.02–4.62 1.63 1.07–2.48 
Cannot say vs no 0.90 0.41–1.99 1.13 0.70–1.83 
My current knowledge is sufficient to advise a patient who wishes to stop smoking 
Yes vs no 1.17 0.59–2.30 1.85 1.37–2.49 
Cannot say vs no 0.96 0.44–2.08 1.27 0.95–1.71 
Smoking prevention should form part of the normal training of health professionals 
Yes vs no 0.94 0.46–1.94 1.28 0.87–1.88 
Cannot say vs no 1.00 0.41–2.47 1.66 1.04–2.64 
Lack of habit 
Yes vs no 0.31 0.18–0.53 0.41 0.32–0.52 
Lack of time 
Yes vs no 1.03 0.59–1.82 1.54 1.20–1.98 
Wish to respect patient’s privacy 
Yes vs no 0.68 0.35–1.29 0.72 0.55–0.94 
Age (continuous variable) 1.04 1.01–1.07 1.02 1.01–1.03 
Ethnicity 
Non-Estonian vs Estonian 1.78 0.83–3.78 1.62 1.10–2.38 
Medical specialty 
Family physician vs dentist 4.27 0.85–21.53 6.75 4.06–11.23 
Specialist doctor vs dentist 1.04 0.48–  2.25 1.55 1.21–  2.00 
Smoking status 
Current vs non-smoker 0.67 0.37–1.20 0.44 0.31–0.62 
Study year 
2014 vs 2002 1.27 0.67–2.39 1.92 1.44–2.56 
* Adjusted for all descriptive variables shown in the table.  
 
 
5.2.4. Desire to quit smoking among physicians (Paper V) 
In 2002, the prevalence of desire to quit smoking among currently smoking 
physicians was 55.3% and in 2014, 52.9% (Table 7). The proportion of physi-
cians who were not sure about quitting decreased from 30.1% in 2002 to 22.2% 
by 2014.   
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Table 7. Desire (%) to quit smoking among currently smoking physicians in Estonia, 
2002 and 2014 
Desire to quit 2002 2014 Men Women Total Men Women Total 
Yes 52.9 56.2 55.3 59.1 49.6 52.9 
No 17.9 13.4 14.6 28.8 22.8 24.9 
Cannot say 29.2 30.4 30.1 12.1 27.6 22.2 
 
 
According to adjusted logistic regression models I and II (Table 8), desire to 
quit smoking was significantly associated with  
− being concerned about the harms of smoking 
− number of previous quit attempts 
− wish to set a good example (only in Model II) 
− medical specialty (dentist).  
 
 
Table 8. Association between desire to quit smoking (yes vs no) and factors related to 
smoking behaviour among physicians in Estonia, 2002 and 2014 
Variable Model I
* Model II** 
OR 95% CI OR 95% CI 
Smoking frequency 
Daily vs occasional 1.83 1.24–2.71 1.56 0.87–2.80 
Concern about harmfulness of smoking 
Concerned vs not concerned 7.95 4.63–13.66 9.06 4.15–19.74 
Number of previous quit attempts 
1–2 vs none 2.37 1.51–3.73 2.22 1.18–4.17 
3–4 vs none 9.31 5.06–17.13 10.58 4.51–24.79 
5 or more vs none 13.88 6.03–31.95 9.81 3.63–26.49 
Motivation to quit smoking 
Material stimulus vs health 0.71 0.26–1.90 0.38 0.08–1.80 
Setting a good example vs health 1.46 0.85–2.51 2.38 1.12–5.09 
Other vs health 1.05 0.54–2.04 1.99 0.76–5.25 
Medical specialty  
Family physician vs specialist doctor 1.58 0.95–2.62 1.88 0.89–4.01 
Dentist vs specialist doctor 1.76 1.12–2.76 2.42 1.25–4.69 
* Model I adjusted for gender, age and year. 





5.3. Nicotine dependence (Paper VI) 
In the six-item FTND, the answers to five questions did not differ significantly 
between men and women (p > 0.05) (Table 9). Gender difference was found in 
the question concerning preference of smoking more in the morning then during 
the rest of the day. Among men 27.4% and among women 11.9% (p=0.013) 
smoked more in the morning than during the rest of the day.  
 
 
Table 9. Distribution (%) of the results of the six-item FTND with points for calculation 
of ND score  
Questions in FTND FTND points per answer Men Women P-value Total 
How soon after you wake up do you smoke your first cigarette? 
In 5 minutes 3 15.3 8.0 
0.249 
11.2 
In 6–30 minutes 2 29.8 39.1 35.1 
In 31–60 minutes 1 25.7 32.9 29.8 
Later 0 29.1 20.0 24.0 
How many cigarettes a day do you smoke on average? 
≤10 0 42.2 57.8 
0.184 
51.1 
11–20 1 46.0 34.7 39.6 
21–30 2 10.1 6.5 8.1 
≥31 3 1.8 1.0 1.3 
Do you find it difficult to refrain from smoking in the places where it is forbidden (e.g. 
on the airplane, in the cinema)?  
Yes 1 13.6 10.2 0.617 11.7 No 0 86.4 89.8 88.3 
Which cigarette would you hate most to give up?  
First in the morning 1 44.8 40.9 0.872 42.6 Any other 0 55.2 59.1 57.4 
Do you smoke more frequently during the first hours after waking than during the rest 
of the day?  
Yes 1 28.0 11.6 0.013 18.7 No 0 72.0 88.4 81.3 
Do you smoke if you are so ill that you are in bed most of the day?  
Yes 1 24.8 18.4  0.552 21.2 No 0 75.2 81.6 78.8 
 
 
The mean ND score for daily smoking physicians, calculated using FTND, was 
2.8 ± 2.1 (among men 3.2 ± 2.4, and among women 2.7 ± 2.0, p=0.385). 
Almost 40% of daily smoking physicians had moderate or high ND (Table 





Physicians with low ND had a mean age of smoking initiation of 21.0 ± 5.1, and 
physicians with at-least-moderate ND, 18.4 ± 3.3 (p<0.001). 
Adjusted logistic regression analysis showed that having at-least-moderate 
ND was significantly associated with age of smoking initiation (Table 11). 
When the age of smoking initiation increased by one year, the odds of having 
at-least-moderate ND was lower. 
 
Table 10. Distribution (%) of ND among daily smoking physicians in Estonia, 2014 
ND (score) Men Women P-value Total 
Low (0–3) 51.6 67.8 
0.107 
60.8 
Moderate (4–6) 41.3 26.8 33.1 
High (7–10) 7.1 5.4 6.1 
 
Table 11. Results of logistic regression analysing factors associated with ND (at-least-
moderate vs low) among physicians in Estonia, 2014 
Variables OR* 95% CI 
Age of smoking initiation** 0.82  0.72–0.94 
Desire to quit   
No vs yes 1.99 0.76–5.21 
Cannot say vs yes 0.85 0.31–2.35 
Motives to quit   
Wish to set a good example vs health problems 0.77 0.19–3.19 
Other vs health problems 2.48 0.59–10.39 
Cannot say vs health problems 0.53 0.19–1.49 
Previous quit attempts   
1–2 vs none 0.56 0.22–1.40 
3–4 vs none 0.70 0.23–2.07 
5 and more vs none 0.27 0.05–1.44 
Stress as main reason for relapse   
Yes vs no 1.66 0.73–3.77 
* Adjusted for all descriptive variables shown in the table). 
** Continuous variable. 
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6. DISCUSSION 
This research was conducted to explore smoking, attitudes towards smoking 
behaviour, and nicotine dependence among physicians in Estonia in 1982–2014. 
The results showed that smoking prevalence among physicians has declined, but 
compared to 1982, in 2014 physicians started smoking at an earlier age. Physi-
cians’ attitudes towards smoking became more disapproving and physicians 
addressed patients’ smoking habits more often. Physicians who smoked, viewed 
smoking more favourably and were less likely to address patients’ smoking. 
Physicians reported lack of time as a barrier to asking about their patients’ 
smoking habits. More than half of physicians who currently smoked, expressed 
the desire to quit. About 40% of daily smoking physicians had moderate or high 
nicotine dependence. Earlier smoking initiation was associated with higher ND.  
 
 
6.1. Trends in smoking 
Smoking prevalence 
According to the study results, the age-standardized (using European popula-
tion) (Ahmad et al., 2001) prevalence of current smoking among physicians 
declined by nearly three times from 1982 to 2014 in Estonia. In 1982, about one 
fifth, but in 2014, less than one tenth of physicians were current smokers. 
Similar steady decline has been observed in other countries, like Great Britain, 
Australia, the United States, Finland, and Japan (Barengo et al., 2004; Doll et 
al., 1994; Pärna et al., 2005a; Smith, 2008; Smith & Leggat, 2008, 2007; Smith 
& Wada, 2013). The prevalence of current smoking among physicians in 
Estonia was higher than in most developed countries. The results in 2014 were 
comparable to results from Australia and the United States in the 1980s (Nelson 
et al., 1994; Smith & Leggat, 2008).  
The age-standardized prevalence of current smoking declined nearly three 
times among men and more than two times among women in Estonia. Despite 
the overall decline in smoking, the difference between men and women 
persisted, with the prevalence being about three times as high among men than 
among women. Smoking among the general population showed similar 
tendencies. In Estonia, in 2002, the prevalence of current smoking was 52% 
among men and 24% among women, and in 2014, 39% among men and 23% 
among women (NIHD, 2019b). In comparison, among men with higher edu-
cation, the age-standardized prevalence of current smoking was 39% in 2002 
and 22% in 2014 and among women with higher education 21% and 16%, 
respectively (Pärna et al., 2019). Globally, in Central and Eastern Europe, there 
are bigger differences between smoking prevalence among men and women 
than in Western European and Scandinavian countries. Smoking among 
physicians by gender differs by country as well. In Armenia (Movsisyan et al., 
2012) and Japan (Ohida et al., 2012), smoking was more common among men, 
while in Italy (Zanetti et al., 1998), women smoked at higher rates. In Australia 
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(Smith & Leggat, 2008, 2007) and the United States (Smith, 2008; Smith & 
Leggat, 2007), smoking prevalence was almost the same between the sexes. 
Concerning the present study sample, it has to be noted that in Estonia, more 
than 70% of physicians are women. On average, in Europe about 50% of 
physicians are women but in other regions, it’s less (for example, about 25% in 
Africa) (Boniol et al., 2019). 
According to the results of the present study, smoking among physicians in 
Estonia is comparable with the mature smoking epidemic (Davis, 1993). The 
prevalence of smoking among physicians was much lower than in the general 
population. Information on physicians’ smoking indicates the success of 
population-based anti-tobacco campaigns. When smoking among physicians is 




Present study results showed that in all three study years, the majority of 
physicians who smoked currently were daily smokers. Overall, the age-standar-
dized prevalence of daily smoking decreased 3.3 times among men and 2.6 
times among women between 1982 and 2014. Compared to women, the age-
standardized prevalence of daily smoking was 3.7 times as high among men in 
1982, but 3.0 times as high in 2014. The prevalence of never having smoked 
increased about two times among men and about 1.5 among women. 
In Finland, among physicians in 2002, the proportion of daily smoking 
among current smokers was notably lower than among physicians in Estonia 
(Pärna et al., 2005a). Unfortunately, there is no later data from Finland to add to 
the comparison.  
 
Smoking by age groups 
In current study, in 1982–2014, among physicians in Estonia, the biggest 
decline in current smoking was in younger age groups (≤34, 35–44). At the 
same time, the prevalence of never having smoked also increased in younger 
age groups. Thus, the decline in smoking among physicians in Estonia was the 
result of an increase in quitting behaviour and possibly in the higher number of 
non-smokers becoming physicians. Similarly, the decline in smoking among 
physicians observed in the United States has been the result of an increase of 
both quitting behaviour and in the number of non-smokers entering the 
occupation (Nelson et al., 1994). 
The trends of smoking in Estonia reflect the changes in tobacco policies, as 
the decline in smoking prevalence has been steadier since the middle of the 
2000s. This was also the time when Estonia ratified the WHO FCTC (WHO, 
2005) and adopted the renewed Tobacco Act that complied with the 





Initiation of smoking 
In present study, compared to 1982, physicians in Estonia, especially women, 
started smoking at a younger age in 2014. Early age of starting smoking is one 
of the determinant factors of nicotine dependence and smoking temptation 
(Breslau et al., 1993). However, the earlier onset did not appear to influence the 
decline in smoking prevalence. This could be explained by the increasing 
number of non-smokers entering the occupation. According to the Estonian 
Health Interview Surveys in 1996 and 2006, the onset of smoking among the 
adult population showed a similar trend – in 2006 the age of smoking initiation 
was earlier (Leinsalu et al., 1999; Matsi & Oja, 2009). One explanation of the 
earlier start of smoking could be the expansion of tobacco companies to the 
Eastern Europe markets after the collapse of Soviet Union. Chaotic conditions 
and lack of tobacco control policies allowed for extensive campaigns targeting 
young people and women in particular (Gilmore & McKee, 2004).  
 
 
6.2. Attitudes towards smoking behaviour 
6.2.1. Physicians’ views on causal roles of smoking  
in smoking-related diseases 
In current study, compared to 1982, the proportion of physicians agreeing with 
the statements that smoking is a cause or one of the causes of IHD, lung cancer 
and chronic bronchitis, was significantly higher among both men and women in 
2002 and 2014. The proportion of physicians who did not consider smoking as a 
cause in IHD declined from about 15% to about 2% among both men and 
women. For lung cancer, the decline was from about 10% to 1% and for chronic 
bronchitis, from 5% to 1%. The results could be attributed to the improvements 
in physicians’ knowledge about the health effects of smoking and a decline in 
their own smoking over three decades. Medical education and profession 
appears to have an impact on smoking, as physicians know more about the 
harmful effects of smoking and they act as role models by their own behaviour 
in society as well as among their patients (Abdullah et al., 2014; Pipe et al., 
2009; WHO, 2005).  
Among women, compared to current smokers, past and never smokers 
agreed significantly more with the attribution of smoking in all three smoking-
related diseases. Among men, compared to current smokers, past and never 
smokers agreed significantly more only with the statement that smoking is a 
cause of lung cancer. Attribution of a causal role of smoking in smoking-related 
diseases could be associated with the declining social acceptance of smoking in 
society, especially with legal restrictions on smoking in public spaces and mass 
media campaigns (Ministry of Social Affairs, 2014). It has also been shown that 
compared to non-smokers, smokers systematically underestimate the health 
consequences of smoking (Lohur & Pärna, 2016; Meshefedjian et al., 2010; 
Pärna et al., 2005a; Pärna et al., 2005b; Willaing et al., 2003). 
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Among both men and women, compared to non-Estonians, agreement with 
the statements that smoking is a cause of IHD and chronic bronchitis was higher 
among Estonian physicians. Attribution of the role of smoking in lung cancer 
was higher only among Estonian women. Different attitudes towards the causal 
role of smoking in smoking-related diseases among Estonians and non-Esto-
nians might be related to different social environments and differences in 
medical education, as many non-Estonian physicians came to Estonia in adult-
hood and received their medical education outside Estonia, mainly in Russia. 
However, as the number of non-Estonians who did not agree that smoking is a 
cause for smoking-related diseases, was small, the findings should not be over-
estimated. 
It should also be considered that physicians in Estonia have similar educatio-
nal background in terms of smoking prevention knowledge. Therefore, it can be 
speculated that differences in opinion regarding smoking are related to a 
person’s own behaviour and the need to justify the risk behaviour. 
 
 
6.2.2. Attitudes towards smoking 
Present study results showed that physicians’ attitudes towards smoking were 
less approving in 2014 compared to 2002 in Estonia. Agreement with the state-
ments that smoking is very harmful and that it is important to reduce smoking 
among the population was more prevalent in 2014 and less prevalent among 
smoking physicians. This finding is in accordance with previous results 
showing that, compared to non-smokers, smoking physicians agree less that 
smoking is harmful (Pipe et al., 2009). Agreement with the statements, that to 
stop smoking is very hard for many people, so it is better for their health to 
simply continue smoking, and that smoking does not damage health as long as 
otherwise healthy lifestyle is followed, was less prevalent in 2014.  
In current study, among women only, significant association was found 
between agreement with all the statements and study year. Among men, the 
agreement was significantly associated with study year for four out of seven 
statements. These findings could be explained by different patterns of smoking 
behaviour among men and women (Peters et al., 2014; Reid et al., 2009) but 
also due to the fact that men’s behaviour in general is considered to be more 
risk-prone (Harris et al., 2006). The findings also support the notion that, in 
Estonia, social acceptability of smoking has decreased, and attention has turned 
towards prevention and health promotion. This is supported by legal instru-
ments like the Tobacco Act that have set requirements to create a smoke-free 
environment and reduce the availability of tobacco products in Estonia.  
Agreement with all seven statements regarding smoking was significantly 
associated with smoking status among both men and women. Most drastically, 
compared to non-smokers, men who smoked, had six times as high odds to 
agree that smoking is not as dangerous as experts declare, and had seven times 
as high odds to agree that smoking does not damage health if the person leads 
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an otherwise healthy lifestyle. For smokers, the beliefs that smoking is not 
dangerous to health might be because not all persons who smoke will develop 
adverse effects of smoking like lung cancer or other smoking-related diseases.  
The fact that, compared to non-smokers, smoking physicians agreed less that 
it is important to reduce smoking and believe more that smoking is a person’s 
own choice, demonstrated that physicians who smoke might feel the need for 
justification of their own behaviour, especially if they have not developed any 
smoking-related health problems. The findings might also indicate that physi-
cians play down their role in reducing smoking in the population and, with that, 
fail to seize the opportunity to influence smoking behaviour among the general 
population.  
According to the literature, attitudes towards smoking differ by countries. 
For example, among Italian physicians, 80% considered health professionals as 
behavioural models for patients (La Torre et al., 2014). In Serbia, only 61% of 
physicians agreed that healthcare professionals serve as role models for their 
patients and public (Stojanovic et al., 2013). Compared to Finnish physicians, 
Estonian physicians were less conscious of their role as healthy life style 
exemplars in 2002 (Pärna et al., 2005a). Authors suggested that among phy-
sicians in Estonia, there might have been a fear to interfere with other people’s 
behaviour.  
It has been shown before, that physicians’ beliefs about smoking-related 
diseases were consistent with medical evidence (Pärna et al. 2005b). However, 
the results of the present study show that physicians who smoke, may see 
smoking more favourably. These opinions can affect their smoking cessation 
activities, as it has been shown that smokers might not anticipate health 
problems related to smoking (Rahman et al., 2014). 
 
 
6.2.3. Addressing patients’ smoking 
According to current study findings, among both men and women, the age-
standardized prevalence of addressing patients’ smoking habits at least once 
during the last 7 days was higher in 2014 than in 2002. The change was 
significant among women only. 
Addressing patients’ smoking has increased among physicians worldwide. 
For example, in the USA, it was not common for physicians to address patients’ 
smoking in 1990s and 2000s (Abdullah et al., 2014), but in 2018, 65% of 
patients were asked about smoking status (Tibuakuu et al., 2019). In Romania in 
2011, more than 80% of patients were asked about their smoking status (CDC, 
2013). In 2009–2010, in Poland, 57% and in Russia, 45% of patients reported 
that they were asked if they smoked by a health care provider (CDC, 2013). 
In current study, the agreement that it is doctors’ responsibility to convince 
people to stop smoking, that smoking prevention should be part of the normal 
training and that physicians should have smoking related materials to give out 
to patients if needed, was significantly higher in 2014 compared to 2002. The 
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findings indicate the need for more comprehensive training in smoking cessa-
tion for physicians. Tobacco control is included in the curriculum of medical 
students but is covered under different subjects. 
According to present study results, the proportion of physicians who agreed 
that lack of time was a barrier to asking patients about smoking was signifi-
cantly higher in 2014 compared to 2002. In previous studies, lack of time has 
been one of the most commonly reported barriers for physicians in addressing 
patients’ smoking habits (Jradi et al., 2015; Meijer et al., 2019; Pipe et al., 2009; 
Vogt et al., 2005). This creates a challenge for the organization of smoking 
cessation and other preventative care services.  
No significant change between study years was found in the agreement that 
lack of habit or wish to respect patient’s privacy were barriers to addressing 
patients’ smoking. As the agreement with both statements was relatively low, 
the finding could further support the notion that perceived barriers to addressing 
patients’ smoking are related to practical issues, rather than to physicians’ 
attitudes regarding engaging in preventative services. 
Among both men and women, addressing patients’ smoking habits was 
significantly associated with agreeing that it is a doctors’ responsibility to con-
vince people to stop smoking, and agreeing that doctors should have smoking-
related hand-out materials. This result could be taken as an indication that 
physicians were ready to intervene.  
Physicians’ higher age was significantly associated with a higher likelihood 
of addressing patients’ smoking, among both men and women. It has been 
shown before that senior physicians are more likely to ask about patients’ 
smoking (Mughal et al., 2018). Offering advice on smoking cessation has also 
been associated with having longer work experience (Alateeq et al., 2016), sug-
gesting that when smoking cessation counselling is needed, the patient should 
be referred to more experienced physicians. 
Among women, addressing patients’ smoking was significantly associated 
with physicians agreeing that their knowledge is sufficient to advise on smoking 
cessation and that smoking prevention should be part of normal training. This 
result could be related to women being more willing to address patients’ 
smoking, but also to the possibility that some results remained undetected 
because of the smaller number of men in the study sample (in the present study 
sample, more than 80% were women). In both years, the gender distribution of 
physicians in the study sample was similar to the physicians’ gender distribution 
in Estonia in general.  
Also, among women, addressing patients’ smoking was significantly asso-
ciated with perceiving a lack of time and a wish to respect patients’ privacy as a 
barrier to addressing smoking habits. These results reflect physicians’ pro-active 
approach to addressing patients’ smoking, which is crucial in overcoming the 
possible barriers. In addition, the findings indicate that by better organizing 
smoking cessation services, better conditions can be created for physicians to 
advise patients on smoking cessation. There are several aspects about smoking 
cessation services that should be considered. For example, how and when brief 
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cessation advice should be provided, when to refer to counselling or how these 
tasks would be best distributed between different levels of health care or within 
the team of specialists involved in the service provision. In the current study, 
the sample consisted only of physicians, so there is no information on how 
much nurses were involved in smoking cessation in different levels of care. 
The present study did not explore physicians’ views and knowledge about 
the organization of smoking cessation in Estonia. As the WHO has previously 
been critical towards tobacco policy in Estonia, expecting a bigger decline in 
smoking prevalence among the general population, especially among people 
with secondary or lower education (WHO, 2011), every effort is needed to 
further reduce smoking among the population.  
Among women only, addressing patients’ smoking was significantly as-
sociated with ethnicity, medical specialty, smoking status, and study year. 
Physicians’ cultural background has been associated with being more likely to 
provide cessation advice (Mughal et al., 2018). In the context of the present 
study, however, the possible reasons might be related to other factors, like, for 
example, age. A more detailed exploration of those aspects is needed to make 
further conclusions. 
Non-smoking women were significantly more likely to ask patients about 
smoking compared to current smokers. It is well-established, that physicians 
who are smokers, might more likely fail to address patients’ smoking habits 
(Alajmi et al., 2017; Stead et al., 2009).  
Among women only, compared to dentists, family physicians and specialist 
doctors were significantly more likely to address patients’ smoking habits. The 
most common setting for smoking cessation advice is primary care. Family 
physicians tend to be more likely to ask patients about smoking (Dülger et al., 
2018; Meijer et al., 2019; Stead et al., 2013).  
 
 
6.2.4. Desire to quit smoking 
According to the present study findings, among currently smoking physicians in 
Estonia, more than half indicated a desire to quit smoking in both 2002 and 
2014. The proportions are comparable, for example, to Poland (in 2004, about 
60% of physicians intended to quit), but were lower than in the Czech Republic 
(about 75% of smokers intended to in 1995) (Smit et al., 2014). Even though the 
proportion of physicians who expressed a desire to quit smoking was similar in 
both years, the prevalence of daily smokers and the proportion of physicians 
who did not want to quit was higher in 2014 than 2002. The higher prevalence 
of daily smokers might indicate that these were people with a stronger ND, who 
might not be determined to quit or are unable to successfully quit because of the 
addiction.   
Among the general population, the studies show that a half to three quarters 
of smokers express a desire to quit (Marques-Vidal et al., 2011) (Myung et al., 
2012). In Estonia, the prevalence of intention to quit was a little over 60% in 
2004, but decreased to 54% by 2018 (NIHD, 2005, 2019a).  
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Desire to quit has been stated as an important factor in smoking cessation, as 
it reflects motivation. On the other hand, desire to quit is different from actually 
intending to quit and has been merely seen to predict quit attempts and not the 
success of cessation  (Prochaska et al., 1993) (Smit et al., 2014). The question-
naire used in this study explored only desire to quit smoking, because the 
survey focus was on smoking behaviour in general.  
In the current study, stress, smoking in proximity and withdrawal symptoms 
were the most reported reasons to restart smoking. These findings are in accor-
dance with previous results (Al-Turkstani et al., 2016). Smoking in proximity 
was the second most mentioned reason, but the prevalence of this reason was 
notably lower in 2014 than in 2002. This finding maybe related to smoking 
decline in general, but also because smoking in health care establishments is 
restricted in Estonia.  
In present study, the most mentioned motivators for quitting were personal 
health problems and wishing to set a good example. Previous findings sug-
gested the same – concern for health and wishing to set a good example have 
been found to be the most important reasons to quit smoking among medical 
staff but also among the general population (Bennasar Veny et al., 2011; Hyland 
et al., 2004). 
Previous studies have also shown a connection between nicotine dependence 
and smoking cessation (Al-Turkstani et al., 2016; Hyland et al., 2004; Vangeli 
et al., 2011). In present study, it was not possible to analyse this association as 
within Estonian physicians’ smoking surveys, nicotine dependence was mea-
sured only in 2014.  
Among the sample of physicians in Estonia, desire to quit smoking was 
found to be significantly associated with being concerned about the harmfulness 
of smoking, number of previous quit attempts and wishing to set a good 
example. These findings are in accordance with previous studies (Myung et al., 
2012; Vangeli et al., 2011). Attempts to quit have been shown to be associated 
with intention to quit and are considered an important predictor of cessation 
success (Hyland, 2006; Vangeli et al., 2011). In the present study, compared to 
respondents who had had no quit attempts, physicians who had had 1–2, 3–4 or 
5 and more quit attempts had higher odds to desire to quit. Similarly to previous 
findings (Myung et al., 2012; Vangeli et al., 2011), Estonian physicians who 
were concerned about the harmfulness of smoking were more likely to express 
desire to quit. These associations could indicate that a person is aware of the 
damaging effect of smoking, is motivated to quit, has tried but failed and so 
needs cessation support. 
None of the reasons for relapse were significantly associated with desire to 
quit smoking in this study. This might be partly due to small subsamples in the 
study. In previous studies, alcohol consumption has been found to be associated 
with intention to quit smoking. Smokers who had higher number of drinks per 
week were less likely to intend to quit smoking (Myung et al., 2012). The 
questionnaire used to collect smoking data from the physicians for the current 
study did not measure alcohol consumption.  
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In motivators for quitting, only the wish to set a good example was signi-
ficantly associated with desire to quit among physicians. As physicians are con-
sidered role models, it was expected that setting a good example would be a 
significant finding among Estonian physicians as well. Financial stimulus was 
not significantly associated with desire to quit in the present study. This was 
somewhat expected, as physicians can be considered to have a higher socio-
economic status. However, in contrast, among the general population, material 
incentives have been described as important factors in quitting smoking, and 
increasing prices of the tobacco products should be prioritized when designing 
tobacco control programmes (Hill et al., 2014; Hoffman & Tan, 2015).  
The association between desire to quit smoking and medical specialty 
showed that, compared to specialist doctors, dentists had significantly higher 
odds to desire to quit smoking however, no significant association was found 
for family physicians. While this last aspect was unexpected, the finding for 
dentists was predictable, as they are in close contact with the patient and there-
fore aware of the devastating effects of smoking to oral health. The lack of 
notable difference between family physicians and medical specialists could be 
explained by the distribution of specialties among physicians. It has been shown 
elsewhere that, among men, surgeons had the highest prevalence of smoking 
compared to other specialities (Yao et al., 2009). In the current study sample, 
about 10% of medical specialists were surgeons.  
In present study, desire to quit smoking was not significantly associated with 
gender and age among physicians in Estonia. There is little information about 
whether gender is associated with desire and intent to quit smoking worldwide, 
but the findings concerning successful cessation tend to show that women are 
less likely to stay abstinent (Caponnetto & Polosa, 2008; Hyland et al., 2004; 
Marques-Vidal et al., 2011; Piper et al., 2010, 2017; Vangeli et al., 2011). There 
is a possibility that women have less serious health conditions, which would 
otherwise motivate to abstain from relapses. However, as men tend to be less 
active when seeking medical help, their health problems would be more serious, 
and they are more motivated to remain abstinent. 
Older age has also been shown to be a predictor of successful cessation, with 
increased cessation rates observed among those who were aged 45 years or 
older (Hyland et al., 2004). However, intention to quit has been shown to 
decrease with increasing age (Vangeli et al., 2011). These findings might reflect 
a relationship between health issues and quitting smoking, as it has been shown 
that smoking physicians tend to believe that, as many people have smoked for 
their whole lives until old age and not become ill, smoking is not as dangerous 
as experts declare.  
In the current study, no association was found between desire to quit 
smoking and study year. This finding was unexpected, as, between 2002 and 
2014, several major legislative changes occurred in terms of tobacco policy in 
Estonia. Also, most of the major hospitals joined the network for tobacco-free 
health services (NIHD, 2014) and promote smoking cessation among their staff. 
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6.3. Nicotine dependence 
Results of six-item FTND showed that, among daily smoking physicians in 
Estonia, about one tenth smoked their first cigarette in 5 minutes after waking 
up and more than half smoked 10 or less cigarettes a day on average. Most 
physicians did not find it difficult to refrain from smoking in places where 
smoking was forbidden, and about 40% said that they would hate the most to 
give up the first cigarette in the morning. About one fifth smoked more fre-
quently during the first hours after waking in the morning than during the rest of 
the day and when they were so ill that had to stay in bed for most of the day. 
In the present study, the FTND results refer to rather low ND among daily 
smoking physicians, with an average value of 2.8. About 40% of physicians had 
moderate or high ND. Surveys among physicians in Germany in 2018 
(Pförringer et al., 2018), Spain in 2015 (Juárez-Jiménez et al., 2015) and Turkey 
in 2014 (Baltaci et al., 2014) presented that low ND scores were found to be 
most prevalent. Compared to the general population worldwide, Estonian 
physicians’ mean FTND score was similar to those in Germany and Norway 
(score 2.8 in 1990s) but lower than those in the USA (4.0 in the 1990s) and 
China (3.1 in 2013) (Fagerström & Furberg, 2008; Kim et al., 2012; Li et al., 
2015). Unfortunately, there is no ND data for the general population in Estonia 
to add to the comparison. 
The results of the current study showed that ND was significantly associated 
with the age of smoking initiation. The earlier the initiation of smoking was, the 
higher the odds of having higher ND. This result was not surprising, as it is 
shown elsewhere that people who initiate smoking at a younger age are more 
likely to become dependent (Ali et al., 2020). Physicians in Estonia who had at-
least-moderate ND began smoking approximately three years earlier than those 
with low ND. The difference of mean age of smoking initiation among physi-
cians with low ND and with at-least-moderate ND was statistically significant. 
In 2014, physicians in Estonia started smoking at an earlier age than in 1982 or 
2002. 
In the present study, the ND was not significantly associated with the desire 
to quit or motives to quit. Surveys conducted in the USA, the UK, Canada and 
Australia showed that a lower dependence was related to a higher probability of 
intention to quit (Siahpush et al., 2006). In the current study, compared to 
physicians who stated personal health problems as the main motive to quit, the 
odds of having at-least-moderate ND were three times as high among those 
whose main motives to quit were “other reasons”. The group included mainly 
subgroups of physicians who reported material reasons (increase of the price of 
tobacco products, material stimulus to quit smoking) and social pressure as the 
main motives to quit. As the subgroups were very small, the responses were 
categorized into one group and, therefore, associations between at-least-
moderate ND and specific motives to quit could remain undetected. 
The present findings showed no significant association between ND and the 
number of quit attempts or stress as a reason for relapse. However, some of 
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these factors have been found to be related to ND in previous studies. For 
example, previous study data reports on the association between work-related 
stress and smoking intensity among public-sector employees (Kouvonen et al., 
2005) and between work-related stress and the use of addictive substances 
among physicians (Pförringer et al., 2018). These findings would allow to 
hypothesize that ND could be higher among physicians because the profession 
is considered to cause higher levels of stress.  
More than half of currently smoking Estonian physicians expressed a desire 
to quit. The results of the present study, however, indicated that smokers might 
still be facing difficulties to do so and therefore would benefit from cessation 
counselling specifically tailored to physicians’ needs. 
It is acknowledged that smoking addiction involves several components. 
Even though difficulties quitting smoking are related to ND, the latter is far 
from being the only determinant in the addiction. Further analysis is needed to 
explore psychosocial, behavioural, contextual and personal aspects of smoking 
addiction among physicians. 
 
 
6.4. Strengths and limitations of the study 
Strengths of the study 
1. The inclusion of all practising physicians gave an excellent opportunity to 
get a comprehensive overview of smoking behaviour among physicians in 
Estonia.  
2. The similarity of the methodology allowed for comparability and enabled to 
analyse long-term trends of physicians’ smoking behaviour. 
3. The gender distribution among respondents was proportional to the overall 
physician population in Estonia allowing to generalize the findings to all 
physicians. 
4. Physicians are considered a homogenous group in terms of educational 
background which reduces the effect of possible confounders.  
5. The study provided, for the first time, an overview of nicotine dependence 
among physicians.  
 
Limitations of the study 
1. The response rates in the three surveys declined over time, as is the case with 
postal surveys in most populations worldwide (Cook et al., 2009). Lower 
response rates can result in bias as non-respondents may systematically 
differ from respondents. 
2. Self-representation bias should be considered, as smokers tend to under-
estimate the amount smoked (Abdullah et al., 2014). Physicians, knowing 
more about the devastating effects of smoking than the general population, 
may be prone to understatement when reporting smoking information. 
3. The study data was drawn from self-reported surveys and thus the possibility 
of recall-bias should be considered. 
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4. The data of the first study were collected in the Soviet era, and minor 
changes were made in the study design and questions between studies, so the 
findings of long-term trends in the study need to be interpreted with caution.  
5. The size of some sub-groups per study year was small, and hence, the study 
estimates might not be as precise as one might wish.  





Based on the results of the study, it can be concluded that smoking prevalence 
among physicians decreased in 1982–2014 in Estonia and physicians’ attitudes 
towards smoking behaviour became more disapproving. More than one third of 
daily smoking physicians had at-least moderate ND.  
 
The specific conclusions are the following: 
1. Smoking prevalence among physicians in Estonia declined from 1982 to 
2014 being higher among men over the study period. The biggest decrease in 
smoking prevalence was among the younger age groups, but physicians 
started to smoke at an earlier age.  
2. Agreement with the statement that smoking is a cause of IHD, lung cancer, 
and chronic bronchitis increased from 1982 to 2014. The acknowledgement 
of a causal role of smoking in smoking-related diseases was related to physi-
cians’ smoking status. 
3. Compared to 2002, physicians’ attitudes towards smoking were less ap-
proving in 2014. Physicians who smoked viewed smoking more favourably. 
4. Compared to 2002, addressing patients’ smoking habits was more common 
in 2014 but the change was significant among women only. Addressing 
patients’ smoking was associated with agreeing that it is physicians’ respon-
sibility to convince people to stop smoking and that physicians should have 
smoking-related hand-out materials among both genders, but with agreeing 
that lack of time, lack of habit, and wish to respect patients’ privacy among 
women only.  
5. In 2002 and 2014, more than half of currently smoking physicians expressed 
the desire to quit smoking. Desire to quit smoking was associated with 
concern about the harms of smoking to health, higher number of previous 
quit attempts, setting a good example, and medical specialty. 
6. More than one third of daily smoking physicians had moderate or high ND 




8. PRACTICAL IMPLICATIONS 
The findings of this study are useful for policymakers and institutions involved 
in organization and development of smoking prevention training and cessation 
counselling services.  
 
More specific suggestions are the following:  
1. A further decline in smoking among Estonian physicians would require 
smoking cessation services tailored specifically for physicians.  
2. Further development of physicians’ training in smoking prevention would 
enable physicians to routinely address patients’ smoking.  
3. In development of smoking cessation counselling services in Estonia, factors 
related to addressing smoking habits should be considered. For example, 
developing best practice guidelines to normalize attending to patients’ 
smoking habits. 
4. Smoking cessation counselling could be further organized by introducing a 
teamwork-based approach and working towards greater involvement of 
nurses and occupational health specialists in preventive services. 
5. On the basis of measuring ND among physicians, similar data should be 
regularly collected among general population to make smoking cessation 
interventions more effective in Estonia. 
6. Attending to patients’ smoking habits could be facilitated for the physicians 
by considering the possibilities of recording smoking data in a standardized 
way in patients’ health records.  
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SUMMARY IN ESTONIAN 
Eesti arstide suitsetamine, suhtumine suitsetamiskäitumisse ja 
nikotiinisõltuvus: läbilõikelised uuringud 1982–2014 
Tubaka tarvitamine on üks peamisi haigestumuse ja suremusega seotud tervise 
riskitegureid maailmas (WHO, 2009) ning on rahvusvahelises haiguste klassifi-
katsioonis (RHK-10) fikseeritud tubaka tarvitamisest tingitud psüühika- ja 
käitumishäirete diagnoosina (F17) (WHO, 2016). Suitsetamise vähendamine ja 
sellest loobumine toob kaasa haigestumise ning surmade vähenemise (WHO, 
2009). 
Maailma Terviseorganisatsiooni (WHO) andmetel on suitsetamise levimus 
maailmas viimastel kümnenditel vähenenud. Aastal 2007 suitsetas sigarette 
umbes 31% meestest ning 11% naistest ning 2018. aastal 26% meestest ja 9% 
naistest. Euroopas on kõrgeima suitsetamise levimusega Ida-Euroopa riigid, 
näiteks suitsetas Gruusias ja Armeenias 2018. aastal veel ligi 50% meestest. 
Soomes suitsetas 2007. aastal 25% meestest ja 19% naistest ning 2018. aastal 
vastavalt 19% ja 16%. Lätis suitsetas 2007. aastal 48% meestest ja 22% naistest 
ning 2018. aastal 44% meestest ja 21% naistest (WHO, 2020b).  
Eesti 16–64-aastastest täiskasvanutest suitsetas 1990. aastal igapäevaselt 
44% meestest ja 15% naistest. Alates 2006. aastast on igapäevasuitsetamise 
levimus Eesti täiskasvanud rahvastikus pidevalt vähenenud. Aastal 2018 suit-
setas igapäevaselt 23% meestest ja 13% naistest (NIHD, 2019b).  
Arstidel on ühiskonnas oluline roll suitsetamiskäitumise mõjutajana nii indi-
viidi, kogukonna kui riigi tasandil (WHO, 2005) ning arstide endi suitsetamis-
harjumused mõjutavad seda, kas ja kuidas nad pööravad tähelepanu patsientide 
suitsetamisele (Pipe jt, 2009).  
Arstide tubakaepideemia rahvusvahelise mudeli järgi hakkavad ühiskonnas 
arstid suitsetama enne kui kogurahvastik, mistõttu on mudeli esimeses faasis 
arstide suitsetamise levimus võrreldes kogurahvastikuga kõrgem. Kui teadlikkus 
suitsetamisega seotud terviseriskidest kasvab, siis hakkab arstide suitsetamise 
levimus vähenema, millele mõne aja möödudes järgneb kogurahvastiku suitse-
tamine, kuid see jääb arstide suitsetamisest kõrgemaks. Selline olukord on iseloo-
mulik mudeli teisele faasile. Arstide tubakaepideemia mudelit kasutatakse ühis-
konna küpsuse kirjeldamisel (Davis, 1993). Esimeses faasis olevaid riike 
nimetatakse suitsetamise põhjal ebaküpseteks (näiteks Filipiinid, Itaalia, Portugal) 
(La Vecchia jt, 2000; Ravara jt, 2014; WHO, 1997, 2015), teises faasis olevaid 
küpseteks (näiteks Soome, Taani, Eesti) (Pärna jt, 2005d; Smith & Leggat, 2007).  
Maailmas on arstide suitsetamist uuritud pikka aega. Tuntuim arstide suitse-
tamise uuring on Ühendkuningriigi meesarstide kohortuuring, mida alustati 
1951. aastal (Doll, 2004). Ajavahemikul 1951–1991 vähenes Ühendkuningriigi 
meesarstide suitsetamine 62%-lt 18%-ni (Doll jt, 1994). Ka mujal arenenud 
riikides on arstide suitsetamise levimus vähenenud. Austraalias suitsetas 1960n-
datel ligi 30% arstidest, kuid 1997. aastaks oli see vähenenud 3%-le (Smith & 
Leggat, 2008). Taanis suitsetas 2000. aastate alguses 15% arstidest (Smith & 
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Leggat, 2007). Soomes oli 2001. aastal igapäevasuitsetamise levimus meesarsti-
de hulgas ligi 7% ning naisarstide hulgas 4% (Pärna jt, 2005a). Arenenud riiki-
de seas leidub ka erandeid nagu Jaapan, kus 2000. aastal suitsetas 27% mees- ja 
7% naisarstidest, ning Prantsusmaa, kus 1998. aastal suitsetas 32% arstidest 
(Smith & Leggat, 2007). 
Arstide suitsetamist Eestis on uuritud neljal korral (aastatel 1978, 1982, 2002 
ja 2014), mistõttu saab seda pidada meie riigi üheks pikemaajalisemaks tervise-
uuringuks. Aastal 1978 tehtud uuringu andmetel suitsetas 42% mees- ja 20% 
naisarstidest (Väärt jt, 1979). Selle aja kohta ei ole Eesti kogurahvastiku suitse-
tamise levimus teada.  
Arstid peaksid pöörama tähelepanu patsientide suitsetamisele, soovitama 
suitsetajatel suitsetamisest loobuda ning vajaduse korral suunama patsiendid 
edasisele loobumisnõustamisele (CDC, 2013). WHO soovitab loobumisnõusta-
misel juhinduda 5A-mudelist: küsi (ask); soovita (advise); hinda (assess); abista 
(assist); korralda (arrange) (WHO, 2001). Uuringud näitavad, et patsientidelt 
suitsetamise kohta küsimise levimus on riikides väga erinev ja sageli puudub 
arstidel teave patsientide suitsetamisharjumuse kohta (Bryant jt, 2015). Näiteks 
küsis Hollandis 62% ja Ühendkuningriigis 98% arstidest patsientidelt suitseta-
mise kohta, kuid nad tegid seda vaid esimesel visiidil. Regulaarselt küsis pat-
sientidelt suitsetamise kohta 28% Belgia ja 63% Ühendkuningriigi arstidest 
(Stead jt, 2009). Soomes küsis 2000. aastate alguses patsientidelt suitsetamise 
kohta ligi 80% arstidest. Sarnane tulemus saadi 2002. aastal arstide hulgas 
Eestis (Pärna jt, 2005a).  
Patsientide suitsetamisele tähelepanu pööramist mõjutavad mitmed tegurid, 
näiteks arstide hoiakud suitsetamise kui riskikäitumise suhtes, kuid ka arstide 
endi suitsetamine. Kui arst on ise suitsetaja, alahindab ta suitsetamise kahjulik-
kust (Pipe jt, 2009) ning on väiksem tõenäosus, et ta pöörab tähelepanu patsien-
tide suitsetamiskäitumisele (Garfinkel, 1976; Kawakami jt, 1997; Mughal jt, 
2018; Pipe jt, 2009; Puska jt, 2005; Reile & Pärna, 2018; Stead jt, 2009; Tang 
jt, 2013). Ka arvamus, et teadmised ja oskused ei ole piisavad loobumisnõusta-
mise läbiviimiseks, vähendab tõenäosust, et arst patsiendi suitsetamisharjumust 
visiitidel käsitleb (Alateeq jt, 2016; Jradi jt, 2015; Stead jt, 2009; Vogt jt, 2005). 
Lisaks mõjutavad arstide puhul patsientide suitsetamisele tähelepanu pööramist 
korralduslikud tegurid nagu visiidiks ettenähtud aeg, kuid ka tasustamine (Stead 
jt, 2009). Ajapuudus on enim nimetatud takistav tegur patsientide nõustamisel 
suitsetamisest loobumise suhtes (Jradi jt, 2015; Meijer jt, 2019; Vogt jt, 2005). 
Uuringute andmetel soovib kogurahvastikus suitsetajate hulgast pool kuni 
kolmveerand suitsetamisest loobuda (Marques-Vidal jt, 2011; Myung jt, 2012). 
Arstide hulgas tehtud uuringud näitasid, et 2004. aastal soovis Poolas loobuda 
60% suitsetajatest ning 1995. aastal Tšehhis 75% suitsetajatest (Abdullah jt, 
2014). 
Suitsetamisest loobumist mõjutavad tegurid nagu vanus (Marques-Vidal jt, 
2011), sissetulek ja haridus (Myung jt, 2012), ent ka eelnevad loobumiskatsed, 
alkoholi tarvitamine, nikotiinisõltuvus (NS) (Marques-Vidal jt, 2011; Myung jt, 
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2012). Tugevam NS on seotud vähesema eduga suitsetamisest loobumisel (Hy-
land jt, 2004).  
Enam levinud NSi mõõtmise meetod on Fagerströmi test. Selle enesekohase 
küsimustiku tänapäeval kasutatav versioon koosneb kuuest küsimusest. Vas-
tuste põhjal arvutatakse välja nikotiinisõltuvuse tugevuse skoor (vahemikus 0–
10 punkti). Erinevates riikides korraldatud uuringute andmeid võrreldes olid 
1990ndate keskel ja lõpus Fagerströmi testiga saadud keskmised skoorid mada-
laimad Saksamaal ja Norras (mõlemal juhul skoor 2,8) ning kõrgeimad Rootsis 




Uurimistöö üldeesmärk oli anda tõenduspõhine ülevaade Eesti arstide suitseta-
misest, suhtumisest suitsetamiskäitumisse ja nikotiinisõltuvusest aastatel 1982–
2014.  
Töö alaeesmärgid olid järgmised: 
1. kirjeldada arstide suitsetamise trendi aastatel 1982–2014 (I artikkel); 
2. analüüsida arstide hoiakuid suitsetamise rolli suhtes suitsetamisega seotud 
haiguste tekkes aastatel 1982–2014 (II artikkel); 
3. uurida arstide suhtumist suitsetamiskäitumisse aastatel 2002 ja 2014 (III 
artikkel); 
4. kirjeldada arstide tähelepanu pööramist patsientide suitsetamisele ning ana-
lüüsida sellega seotud tegureid aastatel 2002 ja 2014 (IV artikkel); 
5. selgitada välja arstide suitsetamisest loobumise soov ja sellega seotud tegu-
rid aastatel 2002 ja 2014 (V artikkel); 





Töö põhines Eesti arstide 1982., 2002. ja 2014. aasta suitsetamisuuringutel. 
Valimi moodustasid kõik Eestis töötavad arstid. Andmed koguti postiküsitluse 
teel. Aastal 1982 oli valimis 4704 töötavat arsti, kelle andmed saadi Haridus-
ministeeriumist. Küsimustikud saadeti arstidele töökoha aadressil. Uuringu 
kohandamata vastamismäär oli 80,7%. 
Aastal 2002 oli valimis 4140 töötavat arsti, kelle andmed saadi Eesti Haige-
kassa lepingupartnerite andmekogust. Küsimustikud saadeti arstidele töökoha 
aadressil. Mittevastanutele saadeti meeldetuletuskiri koos küsimustikuga 4–6 
nädalat pärast esimese küsimustiku postitamist. Uuringu täpsustamata vastamis-
määr oli 66,3% ja täpsustatud (välja arvatud olid arstid, kes olid pensionile 
läinud, kelle aadress oli vale, kes olid Eestist lahkunud või surnud) vastamis-
määr 67,8%.  
Aastal 2014 koostati valim Eesti tervishoiutöötajate registri andmete põhjal. 
Uuringumaterjalid saadeti arstidele kodusel aadressil, mis saadi nende andmete 
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linkimisel Eesti rahvastikuregistriga. Uuringusse kaasati arstid, kellel oli rah-
vastikuregistris täpne kodune aadress. Valimi moodustas 5666 arsti. Mittevasta-
nutele saadeti kuu möödudes meeldetuletuskiri. Järgmise kuu möödudes saadeti 
mittevastanutele uuesti uuringumaterjalidega ümbrik. Uuringu kohandamata 
vastamismäär oli 52,0% ja kohandatud vastamismäär 53,1%. 
Uuringu küsimustik sisaldas küsimusi soo, rahvuse, töökoha, eriala ja suitse-
tamisharjumuste kohta. Küsiti ka arstide arvamusi suitsetamise ja küsimustikus 
loetletud haiguste tekke vahelise seose kohta. Aastal 2002 lisati küsimustikku 
küsimused suitsetamisse kui riskikäitumisse suhtumise, patsientide suitsetamis-
se suhtumise ja suitsetamisest loobumise kohta. Lisaks sisaldas 2014. aasta 
küsimustik NSi tugevuse määramist võimaldavaid küsimusi.  
Arstide suitsetamise trende käsitlevasse artiklisse (I artikkel) kaasati küsi-
mustikud, kus oli vastatud suitsetamise staatust määravatele küsimustele 
(n=3786 aastal 1982, n=2735 aastal 2002 ja n=2902 aastal 2014). Arvutati 
Euroopa standardrahvastiku (Ahmad jt, 2001) põhjal vanusele standarditud 
suitsetamise (igapäeva-, juhu-, endine, mitte kunagi) levimus 95% usaldus-
vahemikega (UV) ja suitsetamise alustamise keskmine vanus. Suitsetamise levi-
muse muutuse olulise hindamisel kasutati mitteparameetrilist testi.  
Artiklisse, milles käsitleti arstide hoiakuid suitsetamise rolli suhtes suitse-
tamisega seotud haiguste tekkes (II artikkel), kaasati küsimustikud, kus oli 
vastatud suitsetamise staatust ja hoiakuid käsitlevatele küsimustele (n=3504 
aastal 1982, n=2735 aastal 2002, n=2902 aastal 2014). Euroopa standard-
rahvastiku (Ahmad jt, 2001) põhjal arvutati vanusele standarditud suitsetamise 
(igapäeva-, juhu-, endine, mitte kunagi) levimus 95% UVga ning suitsetamise ja 
haiguste seoste väidetega nõustumise levimus. Seejuures nenditi väidetes, et 
suitsetamine on peamine põhjus või üks põhjustest südame isheemiatõve, 
kopsuvähi ja kroonilise bronhiidi tekkes. Seoste hindamiseks väidetega nõus-
tumise ning kirjeldavate tegurite (suitsetamise staatus, vanus, sugu, rahvus, 
uuringuaasta) vahel kasutati logistilist regressiooni. Arvutati kohandatud šansi-
suhted 95% UVga.  
Arstide suhtumist suitsetamiskäitumisse käsitleva artikli (III artikkel) vali-
misse kaasati küsimustikud, kus oli vastatud suhtumist kirjeldavatele väidetele 
ning suitsetamise staatuse määramiseks vajalikele küsimustele. Valimisse kaa-
sati alla 65-aastaste arstide küsimustikud (n=2539 aastal 2002, n=2338 aastal 
2014). Arvutati suitsetamiskäitumisse suhtumist kirjeldavate väidetega nõustu-
mise levimus. Kirjeldavate tunnuste (suitsetamise staatus, vanus, sugu, rahvus, 
elukoht, eriala, uuringuaasta) puhul rühmade erinevuste hindamiseks kasutati 
hii-ruut-testi. Suitsetamisse suhtumist kirjeldavate väidetega nõustumise ja kir-
jeldavate tegurite vaheliste seoste hindamiseks kasutati logistilist regressiooni. 
Arvutati kohandatud šansisuhted 95% UVga. 
Patsientide suitsetamisele tähelepanu pööramist käsitleva artikli (IV artikkel) 
valimisse kaasati alla 65-aastaste arstide küsimustikud, kus oli vastatud pat-
sientidelt suitsetamise küsimise kohta (n=2488 aastal 2002, n=1791 aastal 
2014). Patsientidelt suitsetamise kohta küsimise puhul arvutati Euroopa 
standardrahvastiku (Ahmad jt, 2001) põhjal vanusele standarditud levimus ning 
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valimi jaotus kirjeldavate tunnuste (suhtumine suitsetamiskäitumisse, suitseta-
mise kohta küsimist takistavad tegurid, suitsetamise staatus, vanus, sugu, 
rahvus, eriala, uuringuaasta) järgi. Rühmade erinevuste hindamiseks kasutati 
hii-ruut-testi. Seoste hindamiseks patsientidelt suitsetamise kohta küsimise ja 
kirjeldavate tunnuste vahel kasutati logistilist regressiooni. Arvutati kohandatud 
šansisuhted 95% UVga.  
Suitsetamisest loobumise soovi käsitlevasse artiklisse (V artikkel) kaasati 
alla 65-aastaste suitsetavate arstide küsimustikud, kus oli vastatud suitsetamisest 
loobumise soovi küsimusele (n=322 aastal 2002, n=189 aastal 2014). Arvutati 
suitsetamisest loobumise soovi levimus ning valimi jaotus kirjeldavate tunnuste 
(suitsetamise staatus, hinnang suitsetamise kahjulikkusele, loobumiskatsete arv, 
stress suitsetamise taasalustamise põhjusena, motivatsioon loobuda, vanus, 
sugu, rahvus, elukoht, eriala, uuringuaasta) järgi. Seoste hindamiseks loobumis-
soovi ja kirjeldavate tegurite vahel kasutati logistilist regressiooni. Arvutati 
kohandatud šansisuhted 95% UVga.  
Nikotiinisõltuvust käsitleva artikli (VI artikkel) valimisse kaasati igapäeva-
selt suitsetavate arstide küsimustikud, kus oli vastatud NSi määrata võimalda-
vatele küsimustele (n=171 aastal 2014). Arvutati NSi tugevuse skoor Fager-
strömi nikotiinisõltuvuse testi järgi. Rühmade erinevuste hindamisel kasutati 
Fisheri täpset testi ning t-testi. Seoste hindamiseks nikotiinisõltuvuse tugevuse 
ja kirjeldavate tegurite (suitsetamise alustamise vanus, soov loobuda, motivat-
sioon loobuda, loobumiskatsete arv, stress suitsetamise taasalustamise põhju-
sena) vahel kasutati logistilist regressiooni. Arvutati kohandatud šansisuhted 
95% UVga.  




Suitsetamise trend aastatel 1982–2014 (I artikkel) 
Suitsetamise alustamise keskmine vanus meestel oli 1982. aastal 20,4 ja 2014. 
aastal 19,3 ning naistel vastavalt 24,5 ja 20,4. Võrreldes 1982. aastaga oli 
suitsetamise alustamise vanuse muutus naiste hulgas statistiliselt oluline. 
Uuringuperioodi jooksul vähenes nii meeste kui naiste suitsetamise levimus 
oluliselt (p<0,001). 1982. aastal suitsetas 39,7%, 2002. aastal 20,9% ja 2014. 
aastal 14,3% meestest ning vastavalt 12,2%, 8,0% ja 5,2% naistest. Igapäevaselt 
suitsetas meestest 1982. aastal 38,3%, 2002. aastal 15,0% ning 2014. aastal 
11,7%, naistest vastavalt 10,3%, 4,7% ja 3,9%. Enim vähenes suitsetamise levi-
mus nooremates vanuserühmades (kuni 34-aastaste ja 35–44-aastaste hulgas). 
 
Arstide hoiakud suitsetamise rolli suhtes suitsetamisega seotud haiguste 
tekkes, 1982–2014 (II artikkel) 
Enam kui 80% arstidest nõustus väitega, et suitsetamine on peamine põhjus või 
üks põhjustest südame isheemiatõve, kopsuvähi ja kroonilise bronhiidi tekkes. 
Esimesel uuringuaastal oli südame isheemiatõve puhul selle väitega nõustumise 
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osakaal mõnevõrra väiksem kui kopsuvähi või kroonilise bronhiidi väitega. 
Aastaks 2014 oli nii südame isheemiatõve, kopsuvähi kui kroonilise bronhiidi 
puhul nõustumise osakaal enam kui 98% nii meeste kui naiste hulgas.  
Kohandatud logistilise regressioonanalüüsi tulemuste kohaselt oli arstide 
nõustumine väitega, et suitsetamine on südame isheemiatõve põhjus, oluliselt 
suurem eestlaste (vs. mitte-eestlaste) hulgas. Naistest nõustusid selle väitega 
oluliselt enam mittesuitsetajad ja endised suitsetajad (vs. praegused suitsetajad), 
kuid oluliselt väiksem oli nõustumine vanemates vanuserühmades. Väitega, et 
suitsetamine on peamine põhjus või üks põhjustest kopsuvähi tekkes nõustusid 
oluliselt enam arstid, kes olid mittesuitsetajad või endised suitsetajad (vs. prae-
gused suitsetajad). Naiste hulgas oli eestlaste (vs. mitte-eestlased) nõustumine 
oluliselt suurem. Väitega, et suitsetamine on peamine põhjus või üks põhjustest 
kroonilise bronhiidi tekkes oli eestlaste (vs. mitte-eestlased) hulgas nõustumine 
oluliselt suurem nii meeste kui naiste hulgas. Nõustumine oli seotud suitse-
tamise staatusega vaid naiste hulgas. Mittesuitsetajad ja endised suitsetajad (vs. 
praegused suitsetajad) nõustusid oluliselt rohkem väitega, et suitsetamine on 
kroonilise bronhiidi põhjus. Kõikide seisundite puhul nõustuti väidetega 2002. 
ja 2014. aastal oluliselt enam kui 1982. aastal.  
 
Arstide suhtumine suitsetamiskäitumisse, 2002 ja 2014 (III artikkel) 
Võrreldes 2002. aastaga oli 2014. aastal arstide suhtumine suitsetamiskäitu-
misse oluliselt vähem soosiv. Oluliselt enam nõustuti, et suitsetamine on tervi-
sele kahjulik ja suitsetamise vähendamine rahvastikus on oluline.  
Oluliselt vähenes nõustumine järgmiste väidetega: 1) kuna suitsetamise lõpe-
tamine on raske, on mõnikord parem suitsetamist jätkata; 2) suitsetamine ei 
kahjusta tervist, kui inimesel on muus osas tervislik eluviis; 3) kuna paljud 
inimesed on suitsetanud kogu elu kõrge eani ega ole haigestunud, tähendab see, 
et suitsetamine ei ole nii ohtlik, kui eksperdid väidavad; 4) suitsetamine on 
inimese enda asi; 5) suitsetamine on kahjulik vaid siis, kui suitsetatakse üle 10 
sigareti päevas. Suitsetavate mees- ja naisarstide (vs. mittesuitsetavad arstid) 
suhtumine suitsetamisse oli soosivam. 
 
Tähelepanu pööramine patsientide suitsetamisele ja sellega seotud tegurid, 
2002 ja 2014 (IV artikkel) 
Võrreldes 2002. aastaga oli 2014. aastal suurem nende arstide osakaal, kes küsi-
sid patsientidelt suitsetamise kohta igal teisel korral, sageli või alati. Aastal 
2002 ei küsinud 15,1% meestest ja 16,4% naistest mitte kunagi patsientidelt 
suitsetamise kohta, aastal 2014 vastavalt 10,6% ja 10,1%.  
Nii meestel kui naiste hulgas oli tõenäosus küsida patsientidelt suitsetamise 
kohta oluliselt suurem neil, kes nõustusid (vs. ei nõustunud), et arsti kohus-
tuseks on saada patsient suitsetamisest loobuma ja et arstidel peaks olema 
suitsetamisteemalisi jaotusmaterjale. Arsti vanuse kasvades suurenes oluliselt 
patsientidelt suitsetamise kohta küsimise tõenäosus.  
Naisarstid,  kes nõustusid (vs. ei nõustunud), et nende teadmised on piisavad 
patsientide nõustamiseks ja et ajapuudus on takistav tegur loobumisnõustamise 
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puhul küsisid patsientidelt suitsetamise kohta oluliselt sagedamini. Naisarstid, 
kes nõustusid, et harjumuse puudus ja soov mitte häirida patsiendi privaatsust 
on takistavad tegurid, küsisid oluliselt vähem patsientide suitsetamise kohta.  
Võrreldes 2002. aastaga küsisid naisarstid 2014. aastal patsientidelt suitseta-
mise kohta oluliselt sagedamini. Vaid naisarstide hulgas oli patsientidelt suitse-
tamise kohta küsimine oluliselt suurem mitte-eestlaste (vs. eestlased) ning pere-
arstide ja eriarstide (vs. hambaarstid) hulgas. Oluliselt vähem küsisid patsienti-
delt suitsetamise kohta suitsetavad (vs. mittesuitsetavad) naisarstid.  
 
Suitsetamisest loobumise soov ja sellega seotud tegurid, 2002 ja 2014  
(V artikkel) 
2002. aastal soovis suitsetamisest loobuda 55,3% arstidest ning 2014. aastal 
52,9%. Arstide osakaal, kes ei olnud loobumissoovis kindlad, oli 2002. aastal 
30,1% ja 2014. aastal 22,2%. 
Soov suitsetamisest loobuda oli oluliselt suurem igapäevaselt suitsetavatel 
(vs. juhuslikult suitsetavatel) arstidel, samuti neil, kes muretsesid suitsetamise 
kahjulikkuse pärast (vs. ei muretsenud). Suurem loobumiskatsete arv oli oluli-
selt seotud suurema sooviga sitsetamisest loobuda. Oluliselt rohkem soovisid 
suitsetamisest loobuda need arstid, kellele oli tähtis olla heaks eeskujuks. Eriala 
järgi oli soov loobuda oluliselt suurem hambaarstidel (vs. eriarstid). 
 
Arstide nikotiinisõltuvus ja sellega seotud tegurid 2014. aastal (VI artikkel) 
Igapäevaselt suitsetavate arstide hulgas oli keskmine nikotiinisõltuvus Fager-
strömi testi järgi 2,8±2,1 (meestel 3,2±2,4 ja naistel 2,7±2,0, p=0,385). 
Ligi 40%-l igapäevaselt suitsetavatest arstidest oli mõõdukas või tugev NS. 
Tugev NS oli 7,1%-l mees- ja 5,4%-l naisarstidest. Meeste ja naiste NS oluliselt 
ei erinenud (p=0,107). Madala NSiga arstide suitsetamise alustamise keskmine 
vanus oli 21,0±5,1, kuid vähemalt mõõduka NSiga arstide hulgas 18,4±3,3 
(p<0,001). Suitsetamise varasem alustamine oli oluliselt seotud vähemalt mõõ-
duka NSi tekkega.  
 
Järeldused 
Uuringu tulemustest nähtub, et Eesti arstide suitsetamise levimus vähenes aasta-
tel 1982–2014 ning arstide suhtumine suitsetamiskäitumisse muutus vähem soo-
sivaks. Rohkem kui kolmandikul igapäevaselt suitsetavatest arstidest oli vähe-
malt mõõduka tugevusega NS.  
Tööl põhinevad täpsemad järeldused on järgmised:  
1. Suitsetamise levimus arstide hulgas vähenes Eestis ajavahemikul 1982–2014 
ning kogu uuringuperioodi jooksul oli meeste hulgas kõrgem kui naiste 
hulgas. Enim vähenes suitsetamise levimus nooremates vanuserühmades, 
kuid samal ajal hakkasid arstid suitsetama nooremas vanuses.  
2. Nõustumine sellega, et suitsetamine on südame isheemiatõve, kopsuvähi ja 
kroonilise bronhiidi tekkepõhjus suurenes ajavahemikul 1982–2014. Hin-
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nangud suitsetamise põhjuslikkusele nende haiguste tekkes olid seotud arsti-
de suitsetamise staatusega. 
3. Võrreldes 2002. aastaga olid 2014. aastal arstide hoiakud suitsetamise suhtes 
vähem soosivad. Suitsetavad arstid suhtusid suitsetamisse leebemalt.  
4. Võrreldes 2002. aastaga küsisid arstid 2014. aastal patsientidelt suitsetamis-
harjumuse kohta oluliselt sagedamini kuid muutus oli oluline vaid naiste 
hulgas. Tähelepanu pööramine patsientide suitsetamisele oli suurem nende 
mees- ja naisarstide hulgas, kes arvasid, et arsti kohustuseks on saada pat-
sient suitsetamisest loobuma ja et arstidel peaks olema suitsetamisteemalisi 
jaotusmaterjale, kuid vaid naisrstide hulgas, kes arvasid, et ajapuudus, harju-
muse puudus ja soov mitte häirida patsiendi privaatsust on suitsetamise 
kohta küsimist takistavad tegurid.  
5. Nii 2002. kui 2014. aastal soovisid enam kui pooled suitsetavatest arstidest 
suitsetamisest loobuda. Soov suitsetamisest loobuda oli oluliselt seotud 
muretsemisega suitsetamise tervisekahjulikkuse pärast, eelnenud loobumis-
katsete suurema arvuga, sooviga olla heaks eeskujuks ning arsti erialaga.  
6. Rohkem kui kolmandikul igapäevaselt suitsetavatest arstidest oli 2014. aastal 
mõõdukas või tugev NS. Tugevam NS oli oluliselt seotud suitsetamise alus-




Uuringu tulemused on vajalikud poliitikakujundajatele ja organisatsioonidele, 
kes tegelevad suitsetamise ennetamise koolituse ning loobumisnõustamise tee-
nuste korraldamise ja arendamisega.  
Käesoleva uuringu tulemuste põhjal saab teha järgmised ettepanekud: 
1. Arstide suitsetamise levimuse edasiseks vähendamiseks tuleb luua spetsiaal-
selt arstidele suunatud suitsetamisest loobumise teenused. 
2. Arstide poolt patsientide suitsetamisele tähelepanu pööramise soodusta-
miseks tuleb tõhustada suitsetamise ennetamise ja suitsetamisest loobumise 
nõustamise alal väljaõpet arstidele.  
3. Suitsetamisest loobumise nõustamise teenuste arendamisel tuleb arvesse 
võtta tegureid, mis arstide arvates mõjutavad patsientide suitsetamisele 
tähelepanu pööramist. Näiteks on vaja luua ravi- või tegevusjuhendid, et 
soodustada suitsetamise käsitlemist.  
4. Suitsetamisest loobumise nõustamise teenuste edasisel arendamisel tuleb 
rakendada meeskonnatööl põhinevat lähenemist, kaasata ennetavatesse tege-
vustesse enam meditsiiniõdesid ja töötervishoiuspetsialiste. 
5. Arstidel määratud NS põhiselt tuleb koguda samalaadset infot kogurahvas-
tikus eesmärgiga muuta suitsetamisest loobumise sekkumised Eestis efek-
tiivsemaks. 
6. Arstide suitsetamisest loobumise alase sekkumise soodustamiseks tuleb 
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